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ABSTRACT
BIOMIMETIC AND VASCULARIZED 3-D LIVER CANCER MODEL
by
Derek Yip
Anti-angiogenic drugs have failed to show significant extended mortality, except when
co-administered with chemotherapy drugs in clinical trials. This should be predicted by in
vitro models, and yet 2D in vitro models of liver cancer co-administered with these two
types of drugs show increased cell viability, contradicting clinical trials. In vitro models
should mimic clinical trials in order to accurately predict drug outcomes. 2D in vitro
models fail because they lack features of the cancer environment such as presence of
stromal cells and a vasculature.
In order to achieve a biomimetic and vascularized in vitro model that would better
recapitulate the cancer environment, a vascularized 3D in vitro liver cancer model is
proposed in which: 1) heterospheroids, agglomerations of liver cancer HepG2 and
stromal cells, are fabricated and encapsulated in collagen gel; 2) heparin crosslinked, wetspun chitosan microfiber/electrospun chitosan mat tube are coated with endothelial cells;
and 3) spheroids and endothelial coated electrospun chitosan mat tube are embedded
together on Matrigel.
Using the hanging drop method, spheroids are formed and encapsulated in
collagen before exposure to the anti-cancer drug doxorubicin. Cell viability, bile
canaliculi, and cytochrome p450 activity are measured afterwards, showing greater
maintenance of liver cell function for heterospheroids in collagen gel.
Blood vessel constructs are developed using chitosan microfibers/tubes. Chitosan
is modified with heparin and is confirmed by Toluidine blue staining and FTIR (Fourier

Transform Infrared Spectroscopy). Fibronectin and VEGF are then adsorbed showing
greater cell adhesion. Microfibers/electrospun mat tubes are incubated with endothelial
cells and embedded on Matrigel resulting in vascular sprouting.
Triculture spheroids, heterospheroids which also contain endothelial cells, and
cell coated chitosan electrospun mat tube are combined on Matrigel to form a
vascularized model. Triculture spheroids on Matrigel are exposed to anti-cancer drugs,
and vascular sprouts are measured showing expected decrease in length. Spheroids and
cell coated tube together show anastomosis and migration, and fluorescent compounds
injected into the model show their presence in nascent lumen.
Overall, a vascularized model is made which exhibits similar qualities to cancer in
vivo and therefore can be used as a platform for anti-cancer drug testing.

ii

BIOMIMETIC AND VASCULARIZED 3-D LIVER CANCER MODEL

by
Derek Yip

A Dissertation
Submitted to the Faculty of
New Jersey Institute of Technology and
Rutgers, The State University of New Jersey-Newark
in Partial Fulfillment of the Requirements for the Degree of
Doctor of Philosophy in Biomedical Engineering
Department of Biomedical Engineering

August 2016

iii

Copyright © 2016 by Derek Yip
ALL RIGHTS RESERVED
.

APPROVAL PAGE
BIOMIMETIC AND VASCULARIZED 3-D LIVER CANCER MODEL
Derek Yip

Dr. Cheul H. Cho, Dissertation Advisor
Assistant Research Professor of Biomedical Engineering, NJIT

Date

Dr. Bryan Pfister, Committee Member
Associate Professor of Biomedical Engineering, NJIT

Date

Dr. Eun J. Lee, Committee Member
Assistant Professor of Biomedical Engineering, NJIT

Date

Dr. George Collins, Committee Member
Research Professor of Biomedical Engineering, NJIT

Date

Dr. Pranela Rameshwar, Committee Member
Date
Professor of Medicine-Hematology/Oncology, Rutgers-New Jersey Medical School

Dr. Diego Fraidenraich, Committee Member
Date
Assistant Professor of Cell Biology and Molecular Medicine, Rutgers-New Jersey
Medical School

BIOGRAPHICAL SKETCH

Author:

Derek Yip

Degree:

Doctor of Philosophy

Date:

August 2016

Undergraduate and Graduate Education:
•

Doctor of Philosophy in Biomedical Engineering,
New Jersey Institute of Technology, Newark, NJ, 2016

•

Master of Science in Biomedical Engineering,
New Jersey Institute of Technology, Newark, NJ, 2010

•

Bachelor of Arts in Molecular Biology,
UC Berkeley, Berkeley, CA, 2008

Major:

Biomedical Engineering

Presentations and Publications:
Yip, D.; Cho, C.H. "A multicellular 3D heterospheroid model of liver tumor and stromal
cells in collagen gel for anti-cancer drug testing." Biochemical and Biophysical
Research Communications 433(3): 327-332.
Hussain, A.; Collins, G.; Yip, D.; Cho, C.H. "Functional 3-D cardiac co-culture model
using bioactive chitosan nanofiber scaffolds." Biotechnology and Bioengineering
110(2): 637-647.
Shrirao, A.; Kung, F.; Yip, D.; Cho, C.H.; Townes-Anderson, E. “Vacuum-assisted fluid
flow in microchannels to pattern substrates and cells.” Biofabrication 6(3):
035016.
Yip, D.; Beshai, M.; Abu-Hakmeh, A.; Cho, C.H.“Vascularized Chitosan Wet Spun
Fibers for Cancer Models.” 9th Annual Graduate Student Association Research
Day, Newark, NJ, November 2013.
Yip, D.; Cho, C.H. “A Multicellular 3D Heterospheroid Liver Tumor Models for AntiCancer Drug Testing.” Society for Biomaterials, Boston, MA, April 2013.

iv

Yip, D.; Cho, C. H. “Multicellular 3D Heterospheroid Tumor Model for Anti-Cancer
Drug Testing.” 8th Annual Graduate Student Association Research Day, Newark,
NJ, November 2012.
Yip, D.; Cho, C.H. “A Thermosensitive Chitosan/-Glycerophosphate Hydrogel with
Poly-L-Lysine for Liver Tissue Engineering.” 6th Annual Graduate Student
Association Research Day, Newark, NJ, November 2010.

v

ACKNOWLEDGMENT

Many thanks to Dr. Cheul Cho for helping me with paper and grant writing, dealing with
my obfuscation, and giving me guidance during the course of this study.
Thanks to Committee Members: Dr. Bryan Pfister, Dr. Eun J. Lee, Dr. George
Collins, Dr. Pranela Rameshwar, and Dr. Diego Fraidenraich, for reviewing my
dissertation.
Thanks to Lab Neighbors: Anil Shrirao and Venkatakrishnan “Krish” Rengarajan
for accepting my advice and my pacing around.
Thanks to Wai & Ada Yip for their moral and financial support, and for putting
up with my years of searching for myself.
Thanks to Michael & Amy Ling for allowing me into their home, feeding me, and
allowing me to take food.
Thanks to Desmond Ling & Daisy Ling for letting me into their home and dealing
with my travel plans.
Thanks to Alvin Yip, for tech support and for keeping me real.
Thanks to Lab Mates Ali Hussain, Nolan Skop, and Noel Alfonso for giving
guidance and accepting my guidance.
Thanks to Jennifer Min for keeping me sane in college.

vi

TABLE OF CONTENTS

Chapter

Page

1 INTRODUCTION……..............................................................................................

1

1.1 Background Information ....................................................................................

1

1.2 Aims ....................................................................................................................

4

2 SPHEROIDS…...........................................................................................................

5

2.1 Background ….....................................................................................................

5

2.2 Methods...............................................................................................................

9

2.2.1 Culture (HepG2/Fibroblast 3T3-J2)..........................................................

9

2.2.2 Hanging Drop Method (Homospheroids and Heterospheroids) ...............

9

2.2.3 Mitomyocin C ...........................................................................................

10

2.2.4 Collagen Hydrogel ....................................................................................

10

2.2.5 Spheroid Diameter ....................................................................................

11

2.2.6 LIVE/DEAD Assay ..................................................................................

11

2.2.7 Alamar Blue Assay ...................................................................................

11

2.2.8 Cell Tracker Assay ...................................................................................

12

2.2.9 Cytochrome p450 Assay ...........................................................................

13

2.2.10 CLF Staining...........................................................................................

13

2.3 Results…...............................................................................................................

14

2.3.1 Spheroid Diameter ....................................................................................

14

2.3.2 LIVE/DEAD Assay ..................................................................................

15

2.3.3 Alamar Blue Assay (Standard Curve, 2D Monolayer)…..........................

16

vii

TABLE OF CONTENTS
(Continued)

Chapter

Page

2.3.4 Alamar Blue Assay (Homo/Heterospheroid w and w/o Collagen Gel).....

18

2.3.5 Cell Tracker Assay ...................................................................................

18

2.3.6 Alamar Blue Assay (Heterospheroid Drug Exposure) .............................

19

2.3.7 Heterospheroid Drug Exposure (Phase Imaging) .....................................

20

2.3.8 Heterospheroid Drug Exposure (Cytochrome p450 Assay) .....................

21

2.3.9 CLF Staining...............................................................................................

22

2.4 Discussion.............................................................................................................

24

2.4.1 Spheroid.....................................................................................................

24

2.4.2 Co-culture..................................................................................................

27

3 VASCULARIZED MICROFIBER/ELECTROSPUN TUBE...................................

31

3.1 Background ........................................................................................................

31

3.2 Methods ..............................................................................................................

35

3.2.1 Chitosan ....................................................................................................

35

3.2.2 Chitosan Film.............................................................................................

35

3.2.3 Heparin Crosslinking................................................................................

36

3.2.4 Fibronectin Coating...................................................................................

37

3.2.5 Toluidine Blue Staining (Chitosan Film) .................................................

37

3.2.6 FTIR...........................................................................................................

38

3.2.7 Sterilization................................................................................................

38

3.2.8 Actin/DAPI Staining (Chitosan Film) ......................................................

38

viii

TABLE OF CONTENTS
(Continued)
Chapter

Page

3.2.9 Alamar Blue Staining (Chitosan Film) .....................................................

38

3.2.10 Wetspinning ...........................................................................................

39

3.2.11 Instron (Tensile Properties) ...................................................................

39

3.2.12 Wetspun Fiber Diameter.........................................................................

39

3.2.18 Toluidine Blue Staining (Fiber)...............................................................

40

3.2.19 SEM ........................................................................................................

40

3.2.20 VEGF Adsorption (Fiber) .......................................................................

40

3.2.21 Anti-Flk Staining.....................................................................................

40

3.2.22 Cell Culture (MVEC/RAEC)...................................................................

41

3.2.23 Cell Coating ............................................................................................

41

3.2.24 LIVE/DEAD Assay.................................................................................

43

3.2.25 Degradability............................................................................................

43

3.2.26 Electrospinning Chitosan Mat and Tube Formation...............................

44

3.2.27 LIVE/Hoechst Staining............................................................................

46

3.2.28 Vascular Sprouting (Fiber/Tube).............................................................

46

3.3 Results...................................................................................................................

46

3.3.1 Toluidine Blue Staining (Chitosan Film) ................................................

46

3.3.2 FTIR...........................................................................................................

47

3.3.3 Phase Imaging (Chitosan Film) ................................................................

48

3.3.4 Actin/DAPI Staining (Chitosan Film) ......................................................

50

ix

TABLE OF CONTENTS
(Continued)
Chapter

Page

3.3.5 Alamar Blue Assay (Chitosan Film) .........................................................

51

3.3.6 Instron (Tensile Properties).......................................................................

52

3.3.7 Wetspun Diameter (Dry) ..........................................................................

52

3.3.8 Swelling Test ............................................................................................

53

3.3.9 Toluidine Blue Staining (Fiber) ................................................................

56

3.3.10 SEM.........................................................................................................

56

3.3.11 Anti-Flk Staining.....................................................................................

54

3.3.12 Phase Microscopy (MVEC) ....................................................................

57

3.3.13 LIVE/DEAD Staining (Fiber) .................................................................

58

3.3.14 Degradability...........................................................................................

57

3.3.15 LIVE/Hoechst Staining (Tube) ...............................................................

61

3.3.16 Vascular Sprouting (Fiber/Tube) ............................................................

62

3.4 Discussion.............................................................................................................

64

3.4.1 Toluidine Blue Staining and FTIR.............................................................

64

3.4.2 Cell Adhesion..............................................................................................

65

3.4.3 Proliferation................................................................................................

66

3.4.4 Mechanical Properties................................................................................

67

3.4.5 VEGF Binding...........................................................................................

68

3.4.6 Cell Coated Fiber........................................................................................

68

3.4.7 Degradation.................................................................................................

69

x

TABLE OF CONTENTS
(Continued)
Chapter

Page

3.4.8 Cell Coated Tube........................................................................................

72

4 VASCULARIZED CANCER MODEL…..................................................................

75

4.1 Background .........................................................................................................

75

4.2 Methods ...............................................................................................................

83

4.2.1 Culture (HUVEC)......................................................................................

83

4.2.2 Hanging Drop Method (Triculture Spheroid)...........................................

83

4.2.3 Vascular Sprouting (Length)....................................................................

83

4.2.4 Vascular Sprouting (Immunohistochemistry)……...................................

84

4.2.5 Anastomosis .............................................................................................

85

4.2.6 Migration .................................................................................................

85

4.2.7 Fluorescent Dextran/Doxorubicin Injection.............................................

85

4.3 Results...................................................................................................................

86

4.3.1 Vascular Sprouting (Length) …................................................................

86

4.3.2 Vascular Sprout (Immunohistochemistry)…............................................

92

4.3.3 Vascular Sprout (LIVE/DEAD)…............................................................

93

4.3.4 Anastomosis ……….................................................................................

94

4.3.5 Migration ..................................................................................................

96

4.3.6 Fluorescent Dextran Injection...................................................................

98

4.3.7 Doxorubicin Injection………………………............................................

99

4.4 Discussion............................................................................................................. 101

xi

TABLE OF CONTENTS
(Continued)
Chapter

Page

4.4.2 Vascular Sprout Assay............................................................................... 101
4.4.3 Anastomosis............................................................................................... 103
4.4.4 Migration.................................................................................................... 105
4.4.5 Fluorescent Injection..................................................................................

106

5 CONCLUSION........................................................................................................... 108
REFERENCES ………………………………………………………………………... 114

xii

LIST OF FIGURES

Figure

Page

2.1

Hanging drop method fabrication (homospheroid and heterospheroid).......…..…

10

2.2

Spheroid diameter of homospheroids versus heterospheroids................................

14

2.3

LIVE/DEAD assay of spheroid….......……………….………………….……….

15

2.4

Graphs of standard curve, 2D monolayer cultures, and 3D spheroid cultures……

17

2.5

Cell tracker assay of heterospheroid ....………………………………...………...

19

2.6

Cell viability of heterospheroids in collagen gel exposed to drug…….…………

20

2.7

Phase images of heterospheroids in collagen gel exposed to drug….....………...

21

2.8

Graph of cytochrome p450 metabolism of heterospheroids in collagen gel
exposed to drug.........................................………………………………………

22

CLF staining of 2D monolayer versus 3D homospheroids………….………….

23

2.10 CLF staining of heterospheroids exposed to cyclosporine A ………….………

24

3.1

Diagram of EDC/NHS crosslinking.......................................................................

36

3.2

Diagram of heparin crosslinking and fibronectin/VEGF adsorption..……………

37

3.3

Diagram of cell coating (theory)………………………………………………….

39

3.4

Diagram of cell coating (fabrication)......................................................................

42

3.5

Schematic of electrospun mat tube fabrication.......................................................

45

3.6

Photographs of electrospun mat tube......................................................................

45

3.7

Toluidine blue staining of chitosan/heparin films..................................................

47

3.8

FTIR graph of chitosan, heparin, and chitosan heparin films.................................

48

3.9

Phase images of MVEC seeded on chitosan modified films..................................

49

2.9

xiii

LIST OF FIGURES
(Continued)
Figure

Page

3.10 Fluorescent images of actin/DAPI staining of MVEC seeded on chitosan
modified films…........................................………………………………………

50

3.11 Cell viability of MVEC seeded on chitosan modified films…...............................

51

3.12 Graph of stress-strain curve of wetspun fiber.........................................................

52

3.13 Histogram of average diameter of chitosan wetspun fiber…………….................

53

3.14 Histogram of chitosan/chitosan heparin wetspun fibers under dry and wet
conditions...................................................………………………………………

54

3.15 Toluidine blue staining of chitosan/chitosan heparin fibers…...............................

55

3.16 SEM images of chitosan/chitosan heparin fibers. .................................................

56

3.17 Anti-Flk staining of chitosan/chitosan heparin VEGF fibers. ..............................

56

3.18 Phase images of MVEC coated fibers..................................................................

57

3.19 LIVE/DEAD images of RAEC coated fibers.......................................................

58

3.20 Trypan blue staining of non-cell coated chitosan fiber during degradation…….

60

3.21 Phase imaging of cell coated chitosan fiber during degradation. .........................

61

3.22 LIVE/Hoechst staining of cell coated tube............................................................

62

3.23 Phase images of non-cell coated tube....................................................................

63

3.24 Phase images of vascular sprouting from cell coated fiber. ..................................

63

3.25 Phase images of vascular sprouting from cell coated tube. ..................................

64

4.1

Design of vascularized model................................................................................

84

4.2

Triculture spheroid (HUVEC) vascular sprout length exposed to anti-angiogenic
drug Sorafenib.........................................................................................................

86

xiv

LIST OF FIGURES
(Continued)
Figure
4.3

Page

Phase images of triculture spheroid (HUVEC) vascular sprouts exposed to
sorafenib.................................................................................................................

87

Triculture spheroid (RAEC) vascular sprout length exposed to cytotoxic drug
doxorubicin.............................................................................................................

88

Triculture spheroid (RAEC) vascular sprout length exposed to anti-angiogenic
drug sorafenib.........................................................................................................

89

Phase images of triculture (RAEC) spheroids and vascular sprouts exposed to
sorafenib.................................................................................................................

90

Phase images of triculture (HUVEC) spheroids and vascular sprouts exposed to
doxorubicin.............................................................................................................

91

CD31 and DAPI Images of triculture (HUVEC) spheroids and vascular
sprouts....................................................................................................................

92

LIVE/DEAD assay of triculture (RAEC) spheroids following exposure to
doxorubicin............................................................................................................

93

4.10 LIVE/DEAD assay of triculture (RAEC) spheroids following exposure to
sorafenib.................................................................................................................

94

4.11 Anastomosis between cell coated fiber and triculture spheroid.............................

95

4.12 Anastomosis between cell coated tube and triculture spheroid..............................

96

4.13 Migration of triculture spheroid to cell coated fiber...............................................

97

4.14 Migration of triculture spheroid to cell coated tube................................................

98

4.15 Images of vascularized cancer model following injection of FITC dextran….......

99

4.16 Images of vascularized cancer model following injection of doxorubicin……….

100

4.4

4.5

4.6

4.7

4.8

4.9

xv

LIST OF DEFINITIONS

C

Chitosan

CF

Chitosan Fibronectin

CH

Chitosan Heparin

CHF

Chitosan Heparin Fibronectin

CYPA1

Assay to measure cytochrome p-450 activity

ECM

Extracellular Matrix

EDC

1-ethyl-3-(3-dimethylaminopropyl) carbodiimide

EROD

Assay to measure drug metabolism activity

Fibroblast

3T3-J2 fibroblast

HepG2

Hepatocellular carcinoma

MVEC

Human microvacular endothelial cell

NHS

n-hydroxysulfosuccinimide

RAEC

Rat aortic endothelial cell

TCP

Tissue Culture Plate

VEGF

Vascular endothelial growth factor

xvi

CHAPTER 1
INTRODUCTION

1.1 Background Information
Liver cancer is the fifth most common cancer and the third most prevalent cause of cancer
related mortality for men worldwide.[1] Liver cancer is a result of cirrhosis of the liver due
to alcoholism, hepatitis, and/or aflatoxin exposure. In an effort to treat this disease and
other cancer types, anti-angiogenic drugs have been developed.
Judah Folkman’s landmark paper on cancer and angiogenesis, posited that for a
solid tumor to continue growing beyond the limits of diffusion, it must induce
angiogenesis, the process by which new blood vessels are formed from pre-existing ones.
[2] Thus, by preventing angiogenesis, it is believed that the solid tumors will either stop
growing or even regress. This is known as the anti-angiogenic strategy and seems to have
been realized as a cancer treatment with the advent of such anti-angiogenic drugs as
bevacizumab, sunitinib, and sorafenib. However, many of these anti-angiogenic drugs have
shown minimal/negligible results in promoting overall survival of patients.
Besides toxicity/limited efficacy, for which bevacizumab [Avastin] was discontinued as a
treatment for breast cancer, many of these drugs have either been ineffectual or show
minimal success. Bevacizumab, in phase III clinical trials, only showed overall survival in
breast cancer patients of 3 months.[3] Sorafenib, which is considered a success, only shows
significant progression free survival and a modest increase of overall survival of 3 months
to a year. [4-6] Sunitinib showed time to tumor progression of 5.3 months, but also a high
toxicity. [7, 8]
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The reasons for the failure of the anti-angiogenic strategy is not exactly known,
however, many theories for the intrinsic and extrinsic/acquired resistance to antiangiogenic drugs exist. Intrinsic resistance, resistance to the anti-angiogenic drug before
exposure, can be the result of metastatic potential without the need for angiogenesis,
susceptibility to hypoxia, and redundancy of angiogenic mechanisms. Metastatic potential
without the need for angiogenesis is exemplified by breast cancer which may be angiogenic
independent compared to other cancers such as renal or liver cancer. [9] Susceptibility to
hypoxia varies amongst cancer types and even a specific cancer itself as exemplified by
the varied reactions of colon cancer cells lines to bevacizumab. [10] Redundancy of
angiogenic mechanisms is due to the fact that angiogenesis is governed by many different
growth factors such as PDGF, FGF, and VEGF. [11] Despite this, most anti-angiogenic
drugs such as bevacizumab only target VEGF, thus, allowing for continued angiogenesis
via other growth factors. Acquired resistance can occur following anti-angiogenic drug
exposure, when hypoxia brought on by the anti-angiogenic drugs causes an upregulation
in pro-angiogenic growth factors and causes activation of an invasive phenotype. [11-13]
Despite spending hundreds of millions of dollars and putting decades into the
research and development of anti-angiogenic drugs, there is little to show for the effort.
Part of the blame for the failure can be attributed to the failure of in vitro models to
recapitulate the environment which they are modelling during the drug development
process and, thus, accurately predict drug outcomes.
Drug development can be divided into pre-clinical testing and clinical testing. In
pre-clinical testing, a drug is tested on an in vitro model and then followed by animal
studies. This is then followed by ever increasing sized clinical trials. Each phase of
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development, becomes exponentially more expensive and there is a very high attrition rate
as it is estimated that 1 in 5,000 drug candidates is able to reach market.[14] Therefore,
determining a drug’s failure early in the drug development cycle would prevent a great
waste of money and time given that a single drug’s development costs $403 million (US
2000) [15]. Money saved by determining early failure could, thus, be diverted to better
drug candidates. To this end, an appropriate in vitro model would provide a solution to the
problem, unfortunately, most in vitro models fail to accurately model the condition they
are testing.
Most in vitro models are two-dimensional monocultures and therefore fail to
recapitulate the three dimensional nature and cellular heterogeneity of the human body.
Animal models do recapitulate dimensionality and cellular heterogeneity of the human
body, but may differ in their physiology/biochemistry. Numerous examples where animal
models fail to mimic humans abound. Thalidomide was tested on rats and found to be safe,
and, thus, was marketed to relieve morning sickness. However, thalidomide has no effect
in rats, but is a potent teratogen in human beings, resulting in mothers giving birth to
children with deformities, namely deformed or absent limbs. Another difficulty in using
animals as models of disease is that certain diseases such as HIV can only infect primates,
and rodent models of HIV are only accomplished via genetic modification and with limited
success.[16] Therefore, an in vitro model which could incorporate human cells would
better recapitulate human physiology/biochemistry and ultimately, better predict drug
candidates.
A better model is herein proposed to model the aforementioned difficulties found
with anti-angiogeneic drugs on hepatocellular cancer. In order to address the problems
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involved in in vitro testing, a new model must be constructed that incorporates various
aspects of cancer. Specifically, an in vitro model of the hepatocellular carcinoma is
constructed which incorporates liver cancer and a vasculature together. Endothelial cell
coated chitosan microfibers or electrospun tubes with HepG2/fibroblast spheroids
encapsulated in Matrigel will serve as a platform to test anti-angiogenic and chemotherapy
drugs.

1.2 Aims
The goal of this study is to develop a biomimetic and vascularized liver cancer model as a
platform for anti-cancer drug testing. In order to achieve the objective, three aims are
proposed:
•

Aim 1: To develop biomimetic multicellular cancer spheroids for anti-cancer drug
testing.

•

Aim 2: To fabricate and characterize chitosan-heparin micro/nanofiber scaffolds
seeded with endothelial cells to act as tissue engineered blood vessel as a substrate
for angiogenesis.

•

Aim 3: To construct a biomimetic and vascularized liver cancer model combining
multicellular cancer spheroids and chitosan-heparin micro/nanofiber scaffold
recapitulating tumor angiogenesis such that a vasculature is formed to allow
passage of a drug into the spheroid.

CHAPTER 2
SPHEROIDS

Aim 1 is to develop biomimetic multicellular cancer spheroids for anti-cancer drug testing.
We hypothesize that co-cultures of HepG2, liver carcinoma, cells and stromal fibroblasts
fabricated via the hanging drop method into heterospheroids and embedded in ECM gel,
results in a model which recapitulates drug resistance found in cancer in vivo.

2.1 Background
Spheroids are agglomerations of cells shaped like a sphere. In this study, spheroids are used
to promote vascularization. Spheroids which grow to a radius greater than 100 m will
become hypoxic as diffusion is only capable of delivering nutrients and gases up to ~100
m. As a result a hypoxic/necrotic core will start to form in the center of the spheroid. Such
an arrangement in spheroids, in which there are regions of oxia and hypoxia, are similar to
the environment found in cancer and, thus, make spheroids an ideal model system for
cancer drug testing.[17] Furthermore, the three-dimensional arrangement of the spheroid
maintains cell differentiation in regards to albumin production and cytochrome p450
activity when compared to monolayer cultures. [18, 19] [20, 21]
There are two types of spheroids, homospheroids and heterospheroids.
Homospheroids are composed of only one cell type, whereas heterospheroids are
composed of multiple cell types. The multiple cell types present in heterospheroids not
only recapitulate in vivo conditions, in which multiple cell types are present, but aids in
viability as the different cells may interact with each other to promote survival. For this
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study, the liver model is composed of heterospheroids formed from two types of cells:
parenchymal cells HepG2 and non-parenchymal cells 3T3-J2 fibroblasts. HepG2 cells are
liver cancer derived cells and serve to model the liver cancer cells. Fibroblasts are
connective tissue cells responsible for the secretion and remodeling of ECM via the
synthesis of fibrillar collagen and matrix metalloproteases. Co-cultures of hepatocytes and
fibroblasts are shown to improve liver function such as albumin secretion, urea secretion,
and cytochrome p450 activity. [21-28] Cancer-associated fibroblasts aid the parenchymal
cells by not only secreting and remodeling the ECM, but also by upregulating pro-survival
signal transduction pathways. [29-32] These cancer fibroblasts differ from normal
fibroblasts in that they have undergone the “angiogenic switch”. The “angiogenic switch”
refers to a phenotypic change in the fibroblast in which the fibroblast upon exposure to the
tumor microenvironment becomes permanently “activated” producing higher than normal
amounts of ECM and producing a-SMA. [29, 33, 34] Furthermore, these fibroblasts are
known to remodel the environment to promote invasion/metastasis. [35, 36] Besides,
aiding the liver cancer, fibroblasts will also serve to stabilize the structure of growing blood
vessels, which is important in later sections. [29, 30, 37] Thus, by including fibroblasts into
our spheroids, the spheroids will show greater resistance to the anti-cancer drugs as
expected in vivo.
To culture this co-culture of HepG2 and fibroblast cell, the hanging drop method is
used. In the hanging drop method, cells are trypsanized and the appropriate number of cells
are pipetted onto a lid. The lid is then turned over to form the droplets, in which gravity
pull the cells together to form agglomerations/spheroids.

7
Agglomerations/spheroids are harvested by turning over the dish and adding to
liquid to cause droplets with the agglomerations/spheroids to pool together. The advantage
of using the hanging drop method is that it doesn’t require any specialized equipment,
however, a disadvantage to this process is that it forces the formation of spheroids as a
result of gravity, rather than as the result of cancer stem cells and their ability to form
spheroids by themselves. However, this study is not interested in the subject of cancers
stem cells and simply requires spheroids for their physical shape.
Once the spheroids are harvested, they will be encapsulated in collagen gel. ECM,
such as collagen, not only plays an important part in promoting cell survival, but is used in
this study as a barrier to drug diffusion. ECM is critical as a natural scaffold for cells to
adhere to and to prevent anoikis, in which detached non-cancerous cells undergo apoptosis.
Attachment of cells to ECM is known to promote cell viability, metabolism, and
proliferation. Along this mode of thought, attachment of HepG2 to ECM components such
as collagen or Matrigel, or ECM analogues such as chitosan or alginate is known to
improve HepG2 adhesion, phenotype, and proliferation. [19, 38-41] Thus, to aid in HepG2
functionality, collagen gel is added to the model. Collagen is triple helix peptide chains
containing the RGD peptide sequence, responsible for binding with integrins of the cell. In
this study, heterospheroids are not embedded on collagen gel, but rather are embedded in
the collagen gel. In vivo, the path for a drug to reach the tumor requires the molecule to
traverse from the blood stream and through layers of cells including the tunica intima,
tunica media, tunica adventitia, space of Disse, and normal hepatocytes to the tumor. The
collagen gel is, thus, used to prevent the free diffusion of the drug to the spheroid. In other
studies in which spheroids are embedded in gel, the spheroids show greater viability after
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drug exposure compared to non-embedded counterparts. [42] Furthermore, the ECM of the
tumor environment is known to have a higher stiffness than normal tissue due the greater
expression of lysyl oxidase causing the crosslinking of collagen and has the ability to affect
hepatocyte expression of cytochrome p450 metabolism and proliferation. [43, 44] To
mimic this, a higher concentration of collagen gel is used to increase stiffness.
To form a more biomimetic liver cancer model, co-cultures of HepG2 and 3T3-J2
fibroblasts are fabricated via the hanging drop method into heterospheroids and
encapsulated in collagen gel, resulting in a model which recapitulates drug resistance
found in cancer. To measure this resistance, the heterospheroids are exposed to various
drug conditions and measured for relative cell population and bile canaliculi. Measuring
relative cell population via Alamar blue will show the effect of the cancer drugs on cell
viability. The Alamar blue assay is a colormetric assay in which Alamar blue/resorufin is
metabolized to ethoxyresorufin, and as a result changes color which can be used as a
measure of cell population. To prevent, the fibroblast cell population from being included
in this measurement of the effect of the drug on the HepG2 cancer, the fibroblasts are
initially treated with mitomyocin C; a compound known to arrest cell growth. Measuring
functioning of bile canaliculi via cholyl-lysyl-fluorescein (CLF) staining will show the
ability of various 2D and 3D HepG2 cultures to maintain a functioning bile canaliculi, even
after exposure to a choleostatic drug. Cholyl-lysyl fluorescein (CLF) is a fluorescent
compound that resembles the bile salt cholyl glycine and so can be absorbed into the liver
cell and become transported by a bile transporter such as MRP2 (multi-resistant protein 2)
into the bile canaliculi and therefore can show the activity of the bile transporter and
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visualize the bile canaliculi. Such a visual assay can, thus, be used to determine the effect
of choleostatic drugs on liver cells, as choleostatic drugs impair the bile transporters.

2.2

2.2.1

Methods

Culture (HepG2/Fibroblast 3T3-J2)

Human hepatocellular liver carcinoma cell line (HepG2; gift from Dr. Charles Ross,
Rutgers University) cells are cultured in DMEM High Glucose, 10% FBS (Biowest,
Miami, FL), 2% penicillin and streptomycin (P/S, Gibco, Gaithersburgh, MD) and 2mM
L-glutamine (Gibco) at 37oC and 10% CO2. The medium is changed every 2-3 days.
Murine stromal cells (3T3-J2 fibroblasts, purchased from Howard Green, Harvard Medical
School, Boston, MA) are maintained in DMEM plus 10% FBS and 1% P/S.

2.2.2

Hanging Drop Method-Homospheroids and Heterospheroids

The hanging drop technique is used to agglomerate cells into spheroids. For homospheroid
formation, a density of 1,000 HepG2 cancer cells per 30 L is obtained. For heterospheroid
formation, a density of 1,000 HepG2 cells and 1,000 growth-arrested fibroblasts per 30 μL
is obtained. Using a multi-channel pipette, 30 L of cell suspension is pipetted onto the lid
of a 100-mm Petri dish. Lid is flipped onto bottom dish to form droplets. The dish is filled
with sterile deionized water to prevent the droplets from evaporating. Droplets are
incubated for 2 days to form spheroids. Spheroids are then harvested for cell culture.
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Figure 2.1
Hanging Drop Method Fabrication (Homospheroid and Heterospheroid).
Schematic of hanging drop fabrication shows steps in spheroid manufacture. A) shows
liver cancer and stromal cells being pipetted onto a Petri dish lid. B) shows lid being
flipped over to form hanging drops. C) shows heterospheroids being harvested. D) shows
heterospheroids being encapsulated in collagen gel. E) shows anti-cancer drug being
added to heterospheroid/collagen gel system.
2.2.3

Mitomycin C

Fibroblasts are seeded on a tissue culture plate and grown to confluence. Confluent
fibroblasts are growth-arrested by treatment with 12 g/ml of mitomycin C (Sigma) for 2.5
hr. After incubation, fibroblasts are washed and trypsanized prior to hanging drop method.

2.2.4

Collagen Hydrogel

For spheroid culture in collagen gel, approximately 50 spheroids are mixed with 0.3 mL
collagen solution of 9 parts of type I rat tail collagen (1.2 mg/mL, BD Bioscience) and 1
part 10x DMEM. The mixed solution is added into 24-well and incubated for 1 hr at 37C
to form a collagen gel and spheroid encapsulation within the gel. After gelation, 0.5 mL of
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HepG2 culture medium is added and incubated at 37oC and 10% CO2 for anti-cancer drug
testing.

2.2.5

Spheroid Diameter

To examine the spheroid growth over time, spheroids obtained from the hanging drop
method are transferred in a Petri dish for suspension culture. Spheroid images in suspension
culture are captured over 5 days and analyzed by Sigma Scan Pro image software (SPSS,
Inc, Chicago, IL) to measure the diameter.

2.2.6

LIVE/DEAD Assay

For the Live/Dead Assay, 1 M calcein AM and 1 M ethidium homodimer (Invitrogen)
are added to the model and then incubated at 37C for 10 min. Following incubation,
culture/spheroids are visualized with fluorescent microscopy using a Nikon Eclipse TI-5
microscope.

2.2.7

Alamar Blue Assay

Cell population can be measured using the Alamar Blue assay, in which the dye resazurin
is incubated with the spheroids, aliquots are taken after 1 hr, and then measured with a
fluorometer. The absorbance values correlate with the cell population.
10 M resazurin (Fisher) is added to 500 L cell culture media in a 24-well plate
and incubated at 37°C for 1 hr. The samples are collected every day and transferred to 96
well plates for the assay. After the sample collection, the cell culture plates are washed
with PBS and fresh media with the anti-cancer drug is added to each well. Fluorescent
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intensity of the samples are measured using a fluorescent microplate reader (Gemini XPS,
Molecular Devices) at wavelengths 530 nm for excitation and 590 nm for emission.
Alamar blue assay is performed to create:
1) A standard assay (based on fibroblast cell population) in which fibroblasts of
known quantity are inoculated into a 48 well plate and Alamar blue assay performed
the next day.

2) To compare 2D monolayer (HepG2) exposed with and without anti-cancer drug.
50,000 HepG2 cells are inoculated into a 24 well plate and Alamar blue assay is
performed on 0, 1, 2, 3, and 4 days. Culture is exposed to 10 M doxorubicin, which
is changed every day.

3) To compare 3D homospheroids embedded in collagen gel (1.2 mg/mL) exposed
with and without anti-cancer drug on 0, 1, 2, 3, and 4 days. 3D homospheroids are
encapsulated as described in section 2.2.4. Culture is exposed to 10 M
doxorubicin, which is changed every day.
4) To compare 3D heterospheroids embedded in collagen gel (1.2 mg/mL) and 10x
DMEM exposed with and without anti-cancer drug on 0, 1, 2, 3, and 4 days. 3D
homospheroids are encapsulated as described in section 2.2.4. Culture is exposed
to 10 M doxorubicin, which is changed every day.
2.2.8

Cell Tracker Assay

To examine initial cell distribution of HepG2 and fibroblasts within the heterospheroids,
HepG2 are labeled with 1 M 5-chloromethyl fluorescein diacetate (CMFDA, green cell
tracker dye, Invitrogen) and fibroblasts are labeled with 1 M CMTPX red cell tracker dye
(Invitrogen) for 15 min prior to addition as droplets on lid to form hanging drops. The
spheroids are observed by the fluorescent microscopy.
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2.2.9

Cytochrome p450 Assay

Cytochrome P-450 A1 (CYPA1) enzymatic assay is performed by measuring the
ethoxyresorufin-O-deethylase (EROD) activity. The EROD activity assay measures drug
metabolism by measuring the ability of the HepG2 cells to convert ethoxyresorufin to
resorufin. After 5 days of anti-cancer drug treatment, the cultures are induced to produce
CYPA1 by 2 μM 3-methylcholanthren (3-MC, Sigma) for 48 hours. The cells are then
washed well with PBS, followed by 1 hr incubation with 8 μM ethoxyresorufin (Sigma) in
phenol red free culture medium at 37C. The sample medium is collected after incubation
and the fluorescence intensity is measured at 530 nm excitation/580 nm emission
wavelength by the fluorescence microplate reader. Resorufin (Sigma) standards at the
range of 1-1,000 nM are used to determine the sample concentration.

2.2.10 CLF Staining
Bile canaliculi are tubes found between hepatocytes and the excretion of bile salts through
bile transporters into these bile canaliculi can be impaired by exposure to choleostatic
drugs. Cholyl-lysyl-fluorescein (CLF) is a fluorescent bile acid which localizes to the bile
canaliculi, and therefore can be used as a measure of the effect of drugs on a culture of
hepatocytes. Cultures are exposed to 10 μM CLF for 40 min and washed twice before
visualization. For drug conditions, culture or spheroids are exposed to 20 μM cyclosporine
for 2 hrs and washed twice before incubation with CLF.
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2.3

2.3.1

Results

Spheroid Diameter

Spheroid diameters of homospheroids and heterospheroids are measured over 5 days using
the image analysis software. Uniform spheroids with diameters between 300-400 μm are
obtained after 2 days of culture by the hanging drop method. After plating the spheroids in
a Petri dish for suspension culture, the spheroid diameter initially decreases due to cellular
reorganization. The spheroid diameter then increased continuously. The diameter increases
by 35% for homospheroids and by 14% for heterospheroids at day 5. Homospheroids
demonstrated higher spheroid growth rate compared to heterospheroids but there is no
statistically significant differences over the 5 days of culture.

Figure 2.2
Spheroid Diameter of Homospheroids versus Heterospheroids. Graph
compares relative spheroid diameter growth of homospheroid and heterospheroid growth
measured over 5 days. Homospheroids shows greater spheroid diameter growth than
heterospheroids. Ability of fibroblasts to contract may explains why heterospheroids
showed less spheroid diameter growth than homospheroids. Values represent averages ±
SD (n=3).
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2.3.2 LIVE/DEAD
Two types of spheroids are fabricated using the hanging drop technique: homospheroids
and heterospheroids. Homospheroids are composed of one thousand HepG2 liver
carcinoma cells each. Heterospheroids are composed of one thousand HepG2 liver
carcinoma cells and one thousand stromal fibroblasts each. Live/Dead cell staining is
performed with calcein-AM and ethidium homodimer to examine the viability of the cells
within the spheroids formed by the hanging drop method. Figure 2.3 shows phase and
fluorescent images of HepG2 homospheroids stained with the Live/Dead cell dyes. Highly
compact cell aggregates are formed within the spheroids. Most of the cells are stained with
green for live cells and only a few cells express red for dead cells, indicating good cell
viability within spheroids.

Spheroids

Figure 2.3
LIVE/DEAD Assay of Spheroid. Live/Dead assay of spheroid shows
overall green coloration of the spheroid, showing ability of the spheroid to maintain cell
viability.
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2.3.3 Alamar Blue Assay (Standard Curve, 2D Monolayer)
To examine cytotoxicity and proliferation of the spheroids for anti-cancer drug treatment,
Alamar blue (resazurin) assay is performed by treating the cells with 10 M doxorubicin.
Figure 2.4 A) exhibits a standard curve of HepG2 cells at various cell densities determined
by the Alamar blue assay. There is a linear relationship between the fluorescence intensity
and HepG2 cell number. Before testing anti-cancer drug treatment in the 3D spheroid
hydrogel culture system, HepG2 cancer cells are tested in a 2D monolayer culture system
as a control to investigate the effect of doxorubicin. Over the 4 days of the monolayer
culture, treatment with 10 M doxorubicin results in 54% and 17% cell viability on days 2
and 4, respectively as shown in Figure 2.4B). In contrast, the HepG2 cells cultured without
doxorubicin exhibit continuous increase in cell number during the culture period,
demonstrating 334% cell growth (2.3-fold increase) after 4 days of culture. There are
statistically significant differences between no drug and drug conditions on cell viability
and proliferation on days 1-4.
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A)

B)

Alamar blue assay
(standard curve)

2D monolayer culture

C) 3D Spheroid culture

Figure 2.4
Graphs of Standard Curve, 2D Monolayer Cultures, and 3D Spheroid
Cultures. Graphs pertaining to cell viability as measured by the Alamar Blue assay are
shown. A) is a standard showing fluorescence and comparable cell population. B)
compares 2D cell culture growth with or without 10 μM doxorubicin, showing decreased
viability upon drug exposure. C) compares cell growth of homospheroids versus
heterospheroids and with versus without collagen gel, showing greater resistance in
heterospheroids compared to homospheroids in non-gel conditions, and high and no
significant difference between homospheroids and heterospheroids in collagen gel
conditions. Values represent averages ± SD (n=3, P<0.05, *Spheroids in collagen gel vs.
non-gel, # homospheroids non-gel vs. heterospheroid non-gel cultures.
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2.3.4 Alamar Blue Assay (Homo/Heterospheroid w and w/o Collagen Gel)
Alamar blue assay in the 3D spheroid cultures reveals that 3D homo- and heterospheroid
cultures in collagen gel show significantly higher drug resistance to 2D cell cultures after
4 days of doxorubicin drug treatment as shown in Figure 2.4C). Homospheroids in collagen
gel culture system show more drug resistance than those not cultured in collagen gel.
Similar results are observed in heterospheroid cultures. Among cell cultures without
collagen gel, heterospheroid culture show significantly higher drug resistance than
homospheroids and 2D monolayer cultures, but no significant difference in collagen gel
cultures. Results of this study indicate that stromal fibroblasts and collagen hydrogel
culture system provide more resistance to the anti-cancer drug.

2.3.5

Cell Tracker Assay

To monitor HepG2 and fibroblasts within the heterospheroids, cells are labeled with two
different fluorescent cell tracker dyes prior to spheroid formation and observed by
fluorescent microscopy after spheroid formation by the hanging drop method. As shown in
Figure 2.5, two cell types form the heterospheroid that are spatially controlled by the
hanging drop method, demonstrating homotypic and heterotypic cell-cell interactions
between HepG2 and fibroblasts. Most of the growth-arrested stromal fibroblasts are
observed in the center core of the spheroids, whereas HepG2 are observed both in the center
core and at the spheroid periphery.
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Figure 2.5
Cell Tracker Dye of Heterospheroid. Cell tracker dye of Heterospheroid
containing HepG2 cells (in green) and fibroblast cells (in red) shows the even distribution
of Cell tracker green stained HepG2 and Cell tracker red stained stromal cells, as evident
by yellow overlap.
2.3.6 Alamar Blue Assay (Heterospheroid Drug Exposure)
Cell viability and growth in the 3D heterospheroid hydrogel culture system with or without
doxorubicin treatment for 4 days are shown in Figure 2.6. 10 M doxorubicin treatment
results in 116% and 89% cell viability on days 2 and 4, indicating high drug resistance
compared to 2D monolayer culture, as shown in Fig. 2.4 B. For the heterospheroid hydrogel
culture condition without doxorubicin, the cell number increased continuously throughout
the culture period, showing 274% cell growth (1.7-fold increase) on day 4.
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Figure 2.6
Cell Viability of Heterospheroids in Collagen Gel Exposed to Drug.
Heterospheroids in collagen gel are exposed to 10 μM doxorubicin and Alamar blue
assay is used to measure cell populations on day 0 through day 4. Upon drug exposure
heterospheroid viability drops. Values represent averages ± SD (n=3, *P<0.05).
2.3.7

Heterospheroid Drug Exposure (Phase Imaging)

Heterospheroid morphology cultured in collagen gel with and without 10 M doxorubicin
treatment at day 4 are shown in Figure 2.7. The doxorubicin treatment for 4 days
suppressed the spheroid growth and results in deterioration of spheroid structure and cell
membranes, whereas the heterospheroids without the drug treatment retains good spheroid
morphology.

21

A)

B)

Figure 2.7
Phase Images of Heterospheroids in Collagen Gel Exposed to Drug.
Heterospheroids are exposed to 10 μM doxorubicin and 10x phase images of A) nonexposed conditions and B) exposed condition are imaged.
2.3.8

Heterospheroid Drug Exposure (Cytochrome p450 Assay)

Cytochrome P-450 A1 (CYPA1) enzymatic assay is performed to assess the drug
metabolism function of HepG2 in 3D heterospheroid culture system with and without the
doxorubicin treatment. The CYPA1 assay measures drug metabolism by measuring the
ability of the HepG2 cells to convert ethoxyresofurin to resorufin. The assay reveals that
heterospheroids in collagen gel show significantly higher drug metabolism function than
those without gel, indicating more drug resistance as shown in Figure 2.8. The resorufin
production rate of heterospheroid culture with 10 M doxorubicin treatment is 0.047 
0.013 [nM/hr] for collagen gel culture and 0.015  0.002 [nM/hr]. Similar results are
observed in the heterospheroid culture without the doxorubicin treatment.
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Cytochrome P450 Drug Metabolism

Figure 2.8
Graph of Cytochrome p450 Metabolism of Heterospheroids in Collagen
Gel Exposed to Drug. Graph compares cytochrome p450 drug metabolism of
heterospheroids with or without drug and with or without collagen gel after 5 days. Graph
shows that heterospheroid culture in collagen gel produces a greater cytochrome p450
metabolism compared to conditions without collagen gel. Values represent averages ± SD
(n=3, *P<0.05, collagen gel vs. non-gel cultures).
2.3.9

CLF Staining

To investigate the uptake and inhibition of fluorescent probe substrate (CLF) into bile
canaliculi, CLF staining is performed on 2D HepG2 culture, 3D homospheroids, and 3D
heterospheroids, with or without exposure to 20M cyclosporine A (transporter inhibitor).
Green fluorescence is present along the edge of the cells, where bile transporters are located
between adjacent hepatocytes. As shown in Figure 2.9B), the 2D HepG2 culture shows no
green fluorescence, indicating no bile canaliculi formation. In contrast, 3D homospheroid
showed strong expression of CLF staining, indicating good bile canaliculi formation.
Similar results are observed in 3D heterospheroids, forming good bile canaliculi formation
as shown by Figure 2.10D). Exposure of 3D heterospheroids to cyclosporine shows a
decrease of green fluorescence, which indicates the efflux of the CLF substrate into bile
canaliculi via MRP2 transporter is blocked by the Cyclosporin A inhibitor.
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A)

B)

C)

D)

Figure 2.9
CLF Staining of 2D Monolayer versus 3D Homospheroids. Bile canaliculi
is imaged using CLF staining at 10x magnification to compare 2D and 3D cultures. A) is
a 2D HepG2 culture and B) is the subsequent CLF stained image. C) is a 3D HepG2
homospheroid culture and D) is the subsequent CLF stained image. 3D spheroids more
brightly express bile canaliculi compared to 2D cultures.
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A)

B)

With Inhibitor

C)

D)

Without Inhibitor

Figure 2.10 CLF Staining of Heterospheroids Exposed to Cyclosporine A (Transporter
Inhibitor). Bile canaliculi is imaged using CLF staining at 10x magnification to compare
cyclosporine exposed and non-cyclopsorine exposed heterospheroids. Fluorescent images
of 3D spheroids show A) phase image and subsequent B) CLF stained image after
exposure to 20M cyclosporine for 2 hrs. Fluorescent images of 3D spheroids show C)
phase image and subsequent D) CLF stained image without exposure to cyclosporine.
The cyclosporine condition shows a greater decrease of CLF staining, than in the control
condition.
2.4 Discussion
2.4.1 Spheroid
A spheroid is an agglomeration of cells shaped like a sphere resulting in a construct which
has three dimensions, much like cancer in the human body. Furthermore, due to its shape,
spheroids prevent the diffusion of oxygen into the core of the spheroid resulting in hypoxia
and necrosis similar to that of a tumor. Due to these reasons, spheroids are used in this
study as an in vitro model of cancer.
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Spheroids are developed using the hanging drop method, in which cells in media
are hung as droplets which form spheroids due to gravity, and are assessed to determine if
such a construct would be a viable system to maintain cells. A LIVE/DEAD cell assay is
performed on a homospheroid, a spheroid composed, in this case, of only the hepatocellular
cancer revealing living cells in green and dead cells in red. As can be seen by Figure 2.3,
the entirety of the spheroid fluoresces green with little to any red, showing that the spheroid
is a viable system to maintain cells.
Spheroid diameter is measured between homospheroids and heterospheroids, and
shows no significant difference between their diameters. Spheroid diameters are often used
as correlative with cell proliferation and growth. The fibroblasts within the heterospheroids
are supposed to improve cell proliferation as it known that co-culture of fibroblasts and
HepG2 cells improve this aspect of HepG2 cells, and yet the conclusion of this experiment
does not support this claim. A theory for the disparity may be the remodeling capabilities
of fibroblasts. Fibroblasts are responsible for remodeling ECM and as such have contractile
capabilities. As such it can be assumed that the fibroblasts are able to contract the spheroid,
effectively decreasing the diameter.
To determine the effectiveness of spheroids as a culture system to maintain cell
viability similar to conditions in vivo after exposure to anti-cancer drugs, 3D
homospheroids and 2D HepG2 cells are incubated with doxorubicin. When exposed to the
drug doxorubicin, the 3D model shows increased resistance to the drug compared to 2D.
Using the Alamar Blue assay, as shown in Figure 2.4, the relative percentages are
calculated. The 3D model in Figure 2.4 C) shows a higher cell population than the 2D
model in Figure 2.4 B) on day 4. Thus, the 3D model shows a greater degree of drug
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resistance than the 2D model, and, thus, mimics in vivo conditions showing the validity of
the 3D model as an in vitro model. As expected, 3D spheroids are able to maintain cell
viability because of the multiple barriers within the culture, including the gel and the layers
of cells, preventing the diffusion of the doxorubicin. Cell-cell contacts promote proviability signaling and a three-dimensional culture increases the number of cell-cell
contacts as each cell is not only in contact with another cell on the same plane, but with
those cells on planes above and below. The results of these cell contacts is improved
function and viability of the cell culture, including improved albumin secretion and
cytochrome p450 activity. [45-47] The three-dimensional culture also has the ability to
promote cancer stem cells/tumor progenitor cells in HepG2 spheroids and spheroid forming
cancer cells in general. [48-50]
Another aspect of dimensionality is drug exposure. In the human body, a drug is
physically blocked from reaching the cancer by the tortuosity of the blood vessels leading
to the cancer, limitations of diffusion through multiple layers of cells, and the overaccumulation of extracellular matrix. [51] The monolayer culture does not have any
physical barrier to prevent exposure of the culture to the drug and so requires only a smaller
dosage of a drug to render the same effect as that of the in vivo condition. To mimic the in
vivo condition, cancer cells are often embedded in hydrogels much like our collagen gel,
which provide an additional physical barrier. [41, 52]. By being more viable than 2D
cultures, the 3D cultures system shows itself to be a more correct drug cancer model.

2.4.2 Co-culture
Two-dimensional cultures as in vitro cancer models are unreliable as they fail to mimic the
complexity of the in vivo conditions that they are modelling, not only in terms of
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dimensionality, but in regards to cell type. The human body consists of more than two
hundred cell types. In terms of drug testing of in vitro cancer models, the lack of similarity
can drastically affect the results of such testing and lead to erroneous conclusions.
To recreate this aspect of the tumor environment, heterospheroids are made in
which spheroids contain one or more cell type, in this case hepatocellular cancer and
fibroblasts. It should be noted here that ideally, the fibroblasts used would be of human
origin and of a cancerous phenotype. However, due to the difficulty in obtaining fibroblasts
with both characteristics, 3T3-J2 fibroblasts were used instead. 3T3-J2 fibroblasts are an
embryonic mouse line and it is assumed due to the culturing of these fibroblasts on a stiff
surface, i.e. the tissue culture plate, and its presence near cancer cells in the spheroid, that
the fibroblasts transform into a cancerous phenotype. In the future, fibroblasts of a human
origin and cancerous phenotype should be used. Cell Tracker imaging is performed on the
cells of the heterospheroid in which hepatocellular cancer cells are labelled in green and
fibroblast cells are labelled in red. As shown in Figure 2.5, the cells distributed randomly
as evident by the uneven distribution of green/hepatocellular and red/fibroblasts cells as
well as large swaths of yellow showing overlap of these two types of cells. When
heterospheroids are grown on collagen gel and exposed to doxorubicin as shown in Figure
2.7, blebbing can be seen around the edges of the spheroid. In the future, TUNEL assay
should be used to determine the presence of apoptosis in these images.
Growing spheroid diameter can be correlated to tumor volume, a measure of cancer
growth in animal studies. To this end, the spheroid diameters of homospheroids and
heterospheroids are compared. It should be expected that given that fibroblasts are known
to improve HepG2 proliferation, that the spheroid diameter of heterospheroid should be
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significantly larger than that of homospheroids. In reality, the opposite is true as shown in
Figure 2.2 in which homospheroids show an average diameter larger than heterospheroids
on days 1 through 5, although not significantly different. Although, fibroblasts are known
to aid in proliferation, they also are known for their contractile ability, hence the fibroblasts
may have caused compaction of the heterospheroid. Tumor volume is often used as a
correlative of tumor growth in animal studies and so the spheroid cannot be compared to
the animal studies in this regard.
Another experiment to determine the effectiveness of heterospheroids, co-cultures
of HepG2 and fibroblasts, versus homospheroids, is to compare their viability after
exposure to doxorubicin as shown by Figure 2.4C). When exposed to the drug doxorubicin,
the heterospheroids without collagen gel show increased resistance to the drug compared
to homospheroids without collagen gel after 4 days exposure to doxorubicin, showing
relative percentage of 17.5  11% compared to 79.1  1.6 %. The reason for
heterospheroid’s resistance to the anti-cancer drugs can be explained by the inclusion of
fibroblasts which are shown to promote resistance of cancer cells towards anti-cancer
drugs. [20, 21, 31, 53, 54] Fibroblasts promote drug resistance in a variety of manners
ranging from the secretion of ECM components, the release of exogenous growth factors,
and the promotion of neoangiogenesis. [31, 55-57] However, when homospheroids and
heterospheroids are incubated in collagen gel, the spheroids show no significant difference
between the conditions, showing comparable viability of 108.7  15.1% and 94.0  12.9%,
respectively. The collagen gel may be the primary reason for drug resistance as it prevents
the diffusion of the drug to the spheroid and so mask any effects of fibroblast drug
resistance. Collagen can act physically and biochemically to promote drug resistance/cell
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viability. Physically, collagen can act as a barrier to prevent the diffusion of drugs and is
used in this study to recapitulate the physical barrier a drug encounters on its path to the
tumor. Most notably, the collagen acts like the space of Disse, which is a layer of collagen
which separates the endothelial cells from the hepatocytes in the liver. Biochemically,
collagen acts as an ECM substrate by which cells can adhere and can transduce signals
through integrins to promote cell viability. This study does not delve into the etiology for
drug resistance caused by collagen, though in the future the etiology of drug resistance/cell
viability could be determined by encapsulating spheroids in alginate gel. Alginate gel can
also act as a physical barrier, however, because it has no binding sites for cells, it does not
act biochemically to promote cell viability. Thus, if spheroids in alginate gel show
comparable viability to spheroids in collagen following exposure to an anti-cancer drug,
then it can be concluded that the gels act primarily as a barrier to drug diffusion, rather than
acting on signaling transduction pathways. Also required is the exposure of collagen
culture to a vehicle/negative control. A matter in which the collagen gel in our study proves
itself dissimilar to the in vivo environment is the amount by which it may act as a physical
barrier to drug diffusion. The average distance between blood vessels is between 100 and
150 μm, and is smaller in regions of the body where there is a higher metabolic need for
oxygen such as in the brain or the liver. As such to be biomimetic, the collagen barrier
should be approximately between 100 and 150 μm, and yet in our study, the collagen
barrier is at least 1 cm or several orders of magnitude higher than that of in vivo conditions.
Thus, the drug must also travel several orders of magnitude higher than it would in vivo,
rendering a higher drug resistance than expected.
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The 3D model is able to prevent choleostatic drugs such as cyclosporine A from
affecting the bile transporters found between hepatocytes of the cell culture. Bile canaliculi
is a thin tube formed between hepatocytes as a conduit for the excretion of bile, but only
when the hepatocytes are properly functioning and, thus, can be used as a measurement of
liver function. To determine the ability of a 3D model to form these bile canaliculi, 3D
heterospheroids and 2D culture of HepG2 are exposed to CLF. The resulting images, as
shown in Figure 2.7, reveal that the 3D model shows a much brighter green fluorescence
of the CLF transported into the bile canaliculi, than the 2D culture. This is evident by the
fluorescence seen surrounding the cells in the 3D model. Thus, the 3D model is superior to
2D cultures in improving liver functionality. The functioning of the bile canaliculi can be
inhibited by the introduction of the choleostatic drug, cyclosporine A. Cyclosporine is a
drug which is a competitive inhibitor of bile transporters and, thus, prevents excretion of
bile acids such as CLF into the bile canaliculi. Cyclosporine A is exposed to a
heterospheroid, and its fluorescence is compared to a non-exposed condition. The nonexposed condition showed greater green fluorescence compared to its exposed counterpart.
Similar maintenance of the bile canaliculi when exposed to choleostatic drugs is evident in
other 3D models such as the sandwich model or in Matrigel. [58-61] In the future, other
such assays of liver function such as the albumin or urea assay should be performed to
determine the effect of these drugs on our model.

CHAPTER 3
VASCULARIZED MICROFIBER/ELECTROSPUN TUBE

Aim 2 is to fabricate and characterize chitosan-heparin micro/nanofiber scaffolds seeded
with endothelial cells to act as tissue engineered blood vessel as a substrate for
angiogenesis. We hypothesize that heparin immobilized chitosan microfibers or
electrospun tube will support enhanced VEGF binding and endothelial cells adhesion for
angiogenesis.

3.1 Background
Diffusion is capable of distributing molecules of nutrients and gases up to 100 µm. As a
result, multicellular organisms with tissues exceeding 100 µm have a vasculature which
greatly expands the surface area and the capability of diffusion. Without this vasculature,
cells may undergo hypoxia and soon die. As a result, the tumor hijacks the angiogenesis
process by releasing pro-angiogenic growth factors to promote angiogenesis and
subsequent vascularization of the tumor. The triculture heterospheroid is a model of the
cancer, however, to complete the model of cancer angiogenesis, a blood vessel construct
needs to incorporated.
We propose two types of blood vessel constructs: chitosan microfibers and
electrospun tubes coated with endothelial cells. In which discrete chitosan
micro/microfibers are crosslinked with heparin for fibronectin and VEGF, and seeded with
endothelial cells to act as tissue engineered blood vessel as a substrate for angiogenesis.
The vasculature is composed of a variety of cell types with their own specific
functions to maintain the vessel. Endothelial cells compose the inner tunica intima of the
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vasculature. For this study, the endothelial lines RAEC and MVEC are used. Although,
human umbilical vascular endothelial cells (HUVEC) would be the ideal cell line to use in
order to recapitulate human physiology due to the cell line’s human origins, their limited
lifespan/Hayflick limit and low rate of cell division makes the cell line difficult to coat and
successfully grow on the chitosan constructs.
Besides, endothelial cells, cells such as smooth muscle cells, help to maintain the
vasculature in normal, healthy tissue; however, in cancer the vasculature grow wild and
hoary due to a lack of these cells. [62-64] An example of such cells not included in this
model are pericytes. Pericytes, or stellate cells in the liver, are responsible for maintaining
and stabilizing blood vessels, as well as providing growth factors and cytokines. [65]
However, although certainly present in the normal and cancer vasculature, pericytes are
may not be necessary for this model of cancer. Cancer vasculature has a tortuous
architecture containing vessels of varying diameters, abnormal vascular branching pattern,
and irregular blood flow.[62-64] Reasons for this include differential expression of growth
factors throughout the cancer.[62-64]. The cancerous pericyte, is loosely attached to the
vasculature, resulting in a failure to maintain and stabilize the blood vessel. [65, 66] What
is more, fibroblasts may be able to form vascular lumen with the endothelium and without
pericytes, thus, abrogating the need for pericytes. [67, 68]
To serve as a scaffold for the endothelial cells, wet spun chitosan fibers and
electrospun chitosan tubes are used. Concerning wetspun chitosan fibers, when chitosan is
exposed to an acid it becomes a liquid, however, becomes a solid when the chitosan/acetic
acid solution comes in contact with a strong basic solution. This chitosan/acetic acid
solution is injected into a strong basic solution of NaOH:EtOH via a 30 gauge syringe
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needle, wet spun fibers are formed with circular circumferences of 100-150 m, similar to
that of the aorta.
The manufacture of electrospun chitosan tubes follows similar lines of construction
as wetspun chitosan fibers. Briefly, electricity is applied to a chitosan/acetic acid solution
such that a circuit is established between a needle of a syringe, from which chitosan is
ejected, and a metal plate. The result is the formation of fibers on the micron scale which
will together form a mat of chitosan. This chitosan mat is rolled onto a needle to form the
tube shape and exposed to a strong basic solution of NaOH:EtOH, before being washed
and dried. The application of this basic solution in particular is applied, as opposed to other
solutions such as NaOH:H2O, because such a solution has been shown to improve adhesion
and proliferation of endothelial cells on chitosan.[69] The chitosan tube is then removed
from the needle after drying. The disadvantage of using the chitosan tube is that the size of
the syringe and the rolled chitosan mat, make such a construct much larger than the
physiological diameters of blood vessels in vivo and therefore such a construct would differ
in properties such as flow.
In both cases, the material chitosan used in the construction of the structures is not
conducive to cell adhesion as it lacks cell binding sites. Thus, in order to aid in cell adhesion
of endothelial cells to the structure as well as promote cell growth and differentiation, the
structures are first modified before inoculation of cells. To this end, fibronectin or VEGF
is included into the wet spun fiber. Fibronectin is a glycoprotein with RGD binding
sequences involved in cellular adhesion. VEGF is a glycoprotein growth factor involved in
the vascularization process. The use of VEGF is prohibitive due to both its expense and its
short half-life. In order to extend this half-life and raise the local concentration VEGF,
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VEGF will be bound to the microfiber mat. Heparin will serve as the binding mediator for
both fibronectin and VEGF, and the microfiber mat. Heparin is a natural
glycosaminoglycan which is able to bind VEGF due to its negatively charged sulfate
groups. Use of covalently bound heparin shows greater adsorption and prolonged release
of the VEGF or other growth factors to the surface of a material other than the material by
itself. [70-73] As well as serving as a binding agent, there exist a synergy between heparin
and VEGF that aids in angiogenesis. [74, 75]
To inoculate the RAEC cells onto the structures, the structures are simply incubated
in high density cell containing media for up to 2 hrs while being shook every 15 min. At
this point, the cell coated wetspun chitosan fiber does not contain a lumen. To form the
lumen within the wetspun chitosan fiber, the chitosan needs to be dissolved out of the
structure and so the structure is incubated with a variety of enzymes to perform the
degradation. Following dissolution of the chitosan, the natural scaffold, i.e., collagen and
other ECM components, will serve to preserve the vessel structure. Chitosanase or
chitinase would be the most likely candidates as enzymes used to degrade chitosan,
however, are cost prohibitive. Instead cellulase is used as it is far cheaper than chitosanase
and has been shown to have similar degrading power to chitosanase by cleaving the
chitosan structure at the same β-glycoside bond. [76] Furthermore, lysozyme is used as it
also far cheaper than chitosanase and is known to effectively degrade chitosan. Enzymes
like cellulase and lysozyme work at an optimal pH which both happen to be around pH 5,
however, cells survive in an environment of 7.4. A compromise between these two
conditions is met by incubating the cell coated fiber in a solution at pH 6. Such a low pH
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will also aid in the dissolution of chitosan as chitosan dissolves into a liquid at a pH lower
than 7.3.
The manner in which the endothelial cells will coat the fiber should produce a nonfenestrated blood vessel as endothelial cells should evenly coated the fiber. Although,
normal liver vasculature is fenestrated, the liver tumor vasculature is not. The liver tumor
vasculature can take on an “arterialized”, i.e., tight, or “capillarized”, i.e., non-fenestrated
phenotype, heretofore known as sinusoidal vasculature. [77-79] In this case, the sinusoidallike vasculature produced by RAEC should more accurately recapitulate the vasculature
found in this particular cancer.
These VEGF coated, heparin cross-linked chitosan fibers provide a scaffold for
RAEC to form into perfusable blood vessels.

3.2
3.2.1

Methods

Chitosan

Two percent chitosan solution is made by stirring medium molecular weight chitosan
(Aldrich) in dH20 with 1% acetic acid overnight. Chitosan/dH20/acetic acid is then
centrifuged at 3000 rpm for 20 min to remove undissolved chitosan. Chitosan solution is
decanted from the pellet. Chitosan solution is sterilized through autoclave treatment.

3.2.2

Chitosan Film

Chitosan solution is pipetted into 48 well plate and allowed to dry overnight. Chitosan
solution is neutralized by the addition of 0.2M NaOH for 10 min. Four conditions tested:
tissue culture plate, chitosan, chitosan heparin, chitosan heparin fibronectin. 500 l of
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media added to each well, followed by the addition of 40,000 MVEC cells into each. 10x
and 20x phase images taken daily followed by Actin/DAPI staining.

3.2.3

Heparin Crosslinking (Chitosan Film)

Films/fiber/tube are incubated in 5mM 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
(EDC) and 2mM n-hydroxysulfosuccinimide (NHS) (Sigma) and 1mg/mL heparin (in
those conditions that require heparin) in HEPES buffer at 37oC overnight.
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Figure 3.1 Diagram of EDC/NHS Crosslinking. Diagram of crosslinking process
shows how EDC and NHS covalently crosslink heparin to chitosan. [151]
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3.2.4

Fibronectin Coating

Due to the cost prohibitive nature of VEGF, fibronectin is used for preliminary testing in
VEGF’s place. Following crosslinking, 10 g/mL fibronectin solution in dH20 is added to
each well and incubated at room temperature overnight.

Heparin

+

EDC

NH2 NH2

+

NHS

Fibronectin

CO CO
NH2 NH2

A)

or
VEGF

CO CO
NH2 NH2

B)

Figure 3.2
Diagram of Heparin Crosslinking and Fibronectin/VEGF Adsorption.
Diagram of heparin EDC/NHS crosslinking and fibronectin/VEGF coating shows A)
Heparin EDC/NHS Crosslinking in which amide groups of the chitosan microfiber and
carboxyl groups of the heparin are cross-linked with EDC/NHS, and B)
Fibronectin/VEGF Coating in which Heparin binding sequences on fibronectin and
VEGF cause binding of the two molecules to heparin.

3.2.5

Toluidine Blue Staining (Chitosan Films)

Toluidine blue (Sigma Aldrich) is a dye which stains sulfate bearing compounds, e.g.,
heparin, dark blue, and therefore, detect the presence of such a compound. Heparin crosslinked fibers are incubated in 3 mg/mL toluidine blue dye for 10 min at room temperature.
Images of heparin cross-linked fibers are taken before and after 10 min staining. Images
analyzed using SigmaScan Pro5 for difference in coloration.
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3.2.6

FTIR

To determine if crosslinking mechanism between chitosan and heparin occurred, a chitosan
film, heparin powder, and chitosan cross-linked heparin film are examined for their
chemical groups using Spectrum 100 FT-IR Spectrometer (Perkin Elmer).

3.2.7

Sterilization

Film (and subsequent fibers and tubes) are sterilized for 20 min under UV radiation before
treatment.

3.2.8

Actin/DAPI Staining

Cells fixed with 4% paraformaldehyde for 10 min at room temperature. Cells are washed
twice in PBS. 1g/mL actin phalloidin (Sigma) in PBS is incubated with the sample in the
dark for 30 min. Cells are washed twice. 1 g/mL DAPI (MP Biomedicals) is added in
PBS and incubated in the dark for 10 min. Cells are visualized using fluorescent
microscopy.

3.2.8

Alamar Blue Assay (Chitosan Film)

Cell population can be measured using the Alamar Blue assay, in which the dye resazurin
is incubated with the spheroids, aliquots are taken after 1 hr, and then measured with a
fluorometer. The absorbance values correlate with the cell population.
10 M resazurin is added to 500 L media and incubated at 37oC for 1 hr. Samples
are collected and 100 L pipetted into 96 well plate in triplicate. Fluorescent intensity of
resazurin was measured using a Gemini XPS fluorescent plate reader at wavelengths 530
nm for excitation and 590 nm for emission. Assay is performed over the course of 3 days.
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3.2.9

Wetspinning Fiber

Chitosan is a gel below a pH 6 and a solid above pH 6. Exploiting this property, a scaffold
can be designed with traits similar to the physical properties of blood vessels in vivo,
namely having a similar diameter of 100-150 m. Chitosan dissolved in acid can be ejected
through a syringe into a basic chemical bath, causing the chitosan to precipitate and assume
the shape of a blood vessel.
Two percent chitosan solution is wet spun by ejecting solution through a 30 gauge
needle into a 1:1 NaOH:EtOH bath stirring at ~350 rpm. Fibers are formed which are
removed from the bath, washed in EtOH, and dried overnight.

3.2.10 Instron (Tensile Properties)
Uniaxial tensile testing using Instron (Model 3343) is used to generate a stress-strain curve
of dry wetspun chitosan fibers in order to determine their mechanical properties. Chitosan
fibers, measuring 1 cm, are placed in pneumatic grips with an initial gauge length of 1 cm.
Tensile testing is then performed with a 1N load and a crosshead extension rate of 10
mm/min. Stress is calculated by dividing force by cross sectional area which is measured
by fiber diameter using caliper. Young’s modulus is calculated as the slope of the linear
elastic region of the tensile stress-strain curve.

3.2.11 Wetspun Fiber Diameter
Using phase microscopy, images are taken and analyzed using SigmaScan Pro5 software
for fiber diameter. Wetspun diameters are measured when fiber are dry or wet. Wet
wetspun fiber are exposed to water for 10 min before diameters are measured.
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3.2.12 Toluidine Blue Staining (Fiber)
Toluidine blue is a dye which stains sulfate bearing compounds, e.g., heparin, dark blue,
and therefore, detects the presence of such a compound. Heparin cross-linked fibers are
incubated in 3 mg/mL toluidine blue dye for 10 min at room temperature. Images of heparin
cross-linked fibers are taken before and after 10 min staining. Images are then analyzed
using SigmaScan Pro5 for difference in coloration.

3.2.13 SEM
Samples are fixed in 2% glutaraldehyde, and after washing and drying, samples are coated
with carbon. Scanning electron microscopy (SEM) (Leo 1530 VP) is then used to visualize
heparin complexes.

3.2.14 VEGF Adsorption (Fiber)
Following incubation in heparin, the fiber and the tube are briefly washed in dH20. The
fiber and the tube are then incubated in 10 g/mL VEGF at room temperature, overnight.

3.2.15 Anti-Flk Staining
To determine the ability of heparin to bind angiogenic growth factors such as VEGF, antiFlk staining is employed to visualize VEGF in red. A chitosan fiber is heparin crosslinked
as previously mentioned. The crosslinked fiber is then exposed to 10 g/mL VEGF
overnight. After washing three times with PBS, anti-Flk, PE antibody (BD Pharmingen,
1:50) is added and incubated at room temperature for 2 hrs. After washing twice with PBS,
the samples are observed with fluorescence microscopy.
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3.2.16 Cell Culture (MVEC/RAEC)
Microvascular endothelial cells (MVEC; purchased from VEC Technologies, Rensselaer,
NY) and Rat aortic endothelial cells (RAEC; a gift Dr. Eun J. Lee’s lab) are cultured in
high glucose DMEM, 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, 2 mM
L-glutamine, 1% Insulin-Transferin-Selenium (ITS), 10 ng/mL VEGF, and incubated in
10% CO2 at 37oC.

3.2.17 Cell Coating
To form discrete blood vessels, RAEC are coated onto fibronectin coated, heparin crosslinked chitosan fibers/tube.
In brief, RAEC are passaged, cells are detached with trypsin, re-suspended in
media, and subsequently centrifuged at 700 rpm for 5 min to obtain a pellet. The cells are
counted using a hematocytometer and approximately 2 million cells are aliquoted into a
vial. Fibers or tubes are submerged in the cell media within the vial and are incubated for
2 hrs and shook every 15 min. After incubation, the cell media and fibers or tube are
relocated into a p35 Petri dish. An additional 1 mL of media is added and the fibers are
allowed to incubate.
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Schematic of immobilization of bioactive
molecules

on chitosan-based microfiber scaffolds for

Figure 3.3
Diagram of Cell Coating (Theory). Immobilization of heparin to chitosan
microfiber scaffold binds VEGF and fibronectin allowing for binding to VEGF-R on
endothelial cells.
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A)

B)

C)

D)

E)

Figure 3.4
Diagram of Cell Coating (Fabrication). Diagram of cell coating fiber and
coring show A) RAEC cells being trypsanized and cells suspended in media, B)
heparin/fibronectin coated fiber being added into cell media and left to incubate for 7
days, C) combination of enzymatic and acidic degradation used to dissolve scaffold, and
D) the eventual formation of patent blood vessel.
3.2.18 LIVE/DEAD Assay
For the Live/Dead Assay, 1 M calcein AM and 1 M ethidium homodimer (Invitrogen)
are added to the model and then incubated at 37C for 10 min. Following incubation,
culture/spheroids are visualized with fluorescent microscopy using a Nikon Eclipse TI-5
microscope.

3.2.19 Degradability
To become a perfusable blood vessel, enzymes and acids are used to dissolve the chitosan
fiber coated with RAEC cells. Fibers coated with cells are incubated in cellulase (12
g/mL) (Sigma Aldrich) and lysozyme (8 g/mL) (MP Biomedicals) in HBSS buffer (pH

44
6). To visualize the lumen, fibers coated with cells are taken at various time points during
incubation.
In order to evaluate the effectiveness of this enzyme mixture, the degradation of the
enzyme mixture is compared to chitosanase. Unless otherwise indicated, degradation is
always performed by cellulose and lysozyme.
Two methods are employed to determine when the fiber has been sufficiently
degraded. The first method is simple phase microscopy in which the fiber is observed and
considered successfully degraded once the black line along the edge of the fiber has
disappeared. The second method is staining the fiber with trypan blue, since trypan blue
stains positively charged materials such chitosan, and observing the degradation of the blue
chitosan material.

3.2.20 Electrospinning Chitosan Mat and Tube Formation
Electrospun mat is prepared by dissolving 8% medium molecular weight chitosan in
trifluoroacetic acid and methylene chloride. A positive voltage of 20 kV is applied to the
solution and delivered through a 22 gauge needle at a rate of 5 mL/hr with a syringe pump.
The electrospun mat is collected on an aluminum plate (10 cm x 10 cm). The distance
between the syringe and the collecting plate is 10 cm. Electrospun mats are stored in a dry
environment to remove acetic acid.
Square sections (1 cm x 1 cm) are rolled tightly around a 22 gauge needle to form
electospun tubes. The electrospun tubes on 22 gauge needles are neutralized in 1M NaOH
for 10 min and washed overnight in dH2O. Electrospun tube is then dried overnight in a
chemical hood.
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A)

B)

C)

Figure 3.5
Schematic of Electrospun Mat Tube Fabrication. Schematic of forming
electrospun mat into a tube is diagramed. A) shows electrospun chitosan mat being
wound tightly around 22 gauge syringe needle, B) shows neutralization of mat in 1M
NaOH:EtOH solution for 10 min and subsequent washing in dH2O overnight, and C)
shows the drying and removal of the chitosan mat to form the chitosan electrospun tube.

Figure 3.6
Photographs of Electrospun Mat Tube. Photographs of finished chitosan
electrospun tubes show dimensions and presence of a hollow lumen.
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3.2.21 LIVE and Hoechst Staining

Calcein AM is used to fluoresce living cells and Hoechst dye is used to stain nuclei, in
order to determine presence of cells on chitosan electrospun tube. 1 M calcein AM and 1
M Hoechst dye are added to the model and then incubated at 37C for 10 min.. Following
incubation, culture/spheroids are visualized with fluorescent microscopy using a Nikon
Eclipse TI-5 microscope.

3.2.22 Vascular Sprouting (Fiber/Tube)
To assess the fiber/tube’s ability to allow angiogenesis to occur, the fiber/tube are
embedded on Matrigel, and images of the vascular sprouting occurring on the fiber/tube
are taken on days 1, 4, and 7. Length of vascular sprouts are measured using SigmaScan
Pro5 software. Due to the possibility that fibers from the electrospun tube could unwind
and form what appear to be vascular sprouts, a non-cell coated tube is also embedded in
Matrigel to serve as a control and determine whether such an event occurs.

3.3 Results

3.3.1 Toluidine Blue Staining (Film)
Toluidine blue staining of a chitosan (control) film and chitosan cross-linked with heparin
film shows that chitosan control film maintains its white coloration following dyeing. In
contrast, chitosan cross-linked with heparin film shows blue coloration following dyeing,
showing that a negatively charged compound has been bound to the chitosan film
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A)

B)

C)

D)

Figure 3.7
Toluidine Blue Staining of Chitosan/Heparin Films. Toluidine blue staining
images are taken. The first two images shows chitosan film (control) A) before staining
and B) after staining. The last two images shows chitosan heparin film A) before staining
and B) after staining. The control condition shows only pale/opaque coloration, compared
to the Prussian blue/purple coloration in the chitosan heparin condition.

3.3.2

FTIR

FTIR graph of the chitosan film, heparin powder, and chitosan crosslinked with heparin
film shows similarity of absorbance peaks between heparin powder and chitosan crosslinked with heparin film at 1230 nm-1 and 1040 nm-1. These peaks represent the SO3
assymetric and symmetric groups, which figure prominently in the chemical structure of
heparin.
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Figure 3.8
FTIR Graph of Chitosan, Heparin, and Chitosan Heparin Films. FTIR graph
of chitosan film, heparin powder, and chitosan crosslinked with heparin film, shows
similarity between chitosan crosslinked with heparin and heparin powder at 1230 nm-1 and
1040 nm-1, which correspond to sulfate groups known to be present in heparin. N=4.
3.3.3

Phase Imaging

The surface properties of a material affects cell viability. As evidenced below the varying
tissue culture and modified chitosan surfaces results in continued adherence to the surface
after six days for tissue culture plate and chitosan heparin fibronectin conditions; and
sloughing off the surface after six days for chitosan and chitosan heparin conditions.
The tissue culture plate is chemically treated to be hydrophilic and therefore ideal for cell
adhesion. Chitosan, though known to be biocompatible, lacks surface binding proteins like
RGD in collagen/gelatin, and therefore cells fail to adhere to chitosan unless modified
appropriately. Chitosan heparin couples the already lackluster cell adhesion properties of
chitosan with heparin; the most negatively known natural substance. Heparin is a
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glycosaminoglycan with several negatively charged sulfate groups which can act by
electrostatically repelling cells, which are negatively charged. Chitosan heparin fibronectin
is modified with fibronectin which negates many of the poor cell adhesion properties of
chitosan and heparin. Fibronectin is a glycoprotein which in conjunction with heparin has
been shown to a have a synergistic effect on cell adhesion and cell viability.

A)

B)

C)

D)

Figure 3.9 Phase Images of MVEC Seeded on Chitosan Modified Films. Phase imaging
of various chitosan films shows cells at 10x magnification on day 1 on A) Tissue Culture
Plate, B) Chitosan, C) Chitosan Heparin, and D) Chitosan Heparin Fibronectin. Chitosan
and Chitosan Heparin films show little cell adhesion. Chitosan Heparin Fibronectin film
shows cell adhesion and spreading.
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3.3.4

Actin/DAPI Staining (Chitosan Film)

Actin/DAPI Staining is performed 1 day after MVEC coating on film. Initial attachment of
cells can be seen in Figure 3.10 A) the tissue culture plate and Figure 3.10 D) the chitosan
heparin fibronectin conditions evident by the stained actin and nuclei. Although, cells have
attached to both, cells in the chitosan heparin fibronectin condition shows greater cell
spreading.

Phase

Actin

DAPI

Actin/DAPI

A)

B)

C)

D)

Figure 3.10 Fluorescent Images of Actin/DAPI Staining of MVEC Seeded on Chitosan
Modified Films. Fluorescent imaging of Actin/DAPI staining of various chitosan films at
10x magnification for A) Tissue Culture Plate, B) Chitosan, C) Chitosan Heparin, and D)
Chitosan Heparin Fibronectin, after 1 day of culture. Chitosan and Chitosan Heparin films
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Less cell attachment can been seen in Figure. 3.10 B) the chitosan and Figure. 3.10 C) the
chitosan heparin conditions as no stained actin or nuclei are witnessed.

3.3.5

Alamar Blue Assay (Chitosan Film)

Alamar Blue Assay shows the relative cell population growth for the three conditions.
Chitosan heparin fibronectin conditions shows greater cell population growth and are
significantly larger than chitosan and chitosan heparin conditions on day 1. These results
support conclusions in Phase and Actin/DAPI imaging, as cells must attach to a surface in
order to receive pro-viability signals. Tissue culture plate and chitosan heparin fibronectin
conditions shows adhesion and chitosan and chitosan heparin conditions did not, the cells
in the tissue culture plate and chitosan heparin fibronectin conditions were able to attach,
spread, and grow, whereas those cells in the chitosan and chitosan heparin conditions were
unable to attach, spread, and grow, initially.

Alamar Blue Assay (Chitosan Film)
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Figure 3.11 Cell Viability of MVEC Seeded on Chitosan Modified Films. Graphs show
the Alamar Blue Assay of MVEC inoculated on varying Chitosan Films. C= chitosan,
CH= chitosan with cross-linked heparin, and CHF= chitosan with cross-linked heparin
and coated with fibronectin. Chitosan Heparin Fibronectin film shows significant
difference compared to Chitosan and Chitosan Heparin on day 1. Chitosan Heparin
Fibronectin film shows no significant difference compared to Chitosan and Chitosan
Heparin films on day 2. Values represent averages ± SD (n=4, *P<0.05) when comparing
C and CH to CHF.
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3.3.6

Instron (Tensile Properties)

Instron testing is used to measure the mechanical properties of the wetspun chitosan fibers,
showing a Young’s modulus of 1767.7  470.8 MPa and ultimate strength to be 51.3 
17.8 MPa. Overall, the chitosan fiber was brittle.

Stress-Strain Curve of Wet Spun Chitosan Fiber

Figure 3.12 A representative graph of Stress-Strain Curve of Wetspun Fiber. Graph
shows the stress-strain curve of a wetspun chitosan fiber. Instron shows Young’s modulus
of the chitosan microfiber to be 1767.7  470.8 MPa and ultimate strength to be 51.3 
17.8 MPa. (n=4)
3.3.7

Wetspun Fiber Diameter (Dry)

The diameter of the wetspun fibers using different gauge needles (30G vs 20G) and with
or without the presence of flow (stir bar rotating a 350 rpm) is determined using SigmaScan
Pro 5 to measure the distances. The average diameter for 30G with flow is 206.57  24.47
m, for 30G without flow is 393  96.57 m, for 20G with flow is 531.93  132.1m, and
for 20G without flow is 1123.86  274.43 m. Overall, there is a trend such that smaller
gauge needles (30G) and flow allow for a smaller wetspun diameter size.
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Figure 3.13 Histogram of Average Diameter of Chitosan Wetspun Fiber. Histogram of
the average diameters of the chitosan wetspun fibers shows that smaller gauge needles and
flow conditions result in smaller diameters. N indicated in histogram, ** P < 0.05.
3.3.8

Swelling Test

Wetspun chitosan fibers are kept dry or made wet, and their respective diameters are
measured for a chitosan control condition and a chitosan heparin crosslinked condition.
The chitosan control condition shows a normalized swelling percentage of 192  24.2,
while the chitosan heparin crosslinked condition shows a normalized swelling percentage
of 154  24.8. Thus, the chitosan heparin crosslinked condition shows less swelling than
the chitosan control.
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Values are mean  SD (n=16)

Wet
Wet

Dry

Dry

Figure 3.14 Histogram of Chitosan/Chitosan Heparin Wetspun Fibers under Dry and
Wet Conditions. Histogram of chitosan control wetspun fibers and chitosan heparin
crosslinked wetspun fibers shows average diameters of the fibers when dry and when wet.
3.3.9

Toluidine Blue Staining (Fiber)

Toluidine blue staining of chitosan heparin fibers shows a change in coloration from
naturally clear fibers to the dark blue/violet colored fibers shown in Figure 3.6. The change
in color is an indication that the toluidine blue dye is bound to the sulfate groups of heparin,
thus, showing the successful covalent crosslinking of heparin to the chitosan fiber.
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A)

B)

C)

Figure 3.15
Toluidine Blue Staining of Chitosan/Chitosan Heparin Fibers. Toluidine
blue staining images of fibers show A) 10x magnification of control chitosan fibers, B) 10x
magnification of heparin cross-linked chitosan fibers, and C) 20x magnification of heparin
cross-linked chitosan fibers. Chitosan control fibers remain opaque in color even after
staining, whereas heparin crosslinked fiber show a Prussian blue/purple coloration.
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3.3.10 SEM
Heparin/fibronectin coated fibers are carbon coated and visualized to show complexes on
chitosan fibers.

A)

B)

Figure 3.16 SEM Images of Chitosan/Chitosan Heparin Fibers. SEM Images of A)
Control (Non-coated) fiber, B) Heparin/fibronectin coated fibers, show the presence of
complexes present in the heparin/fibronectin condition which are not present in the control
condition.
3.3.11 Anti-Flk Staining
Anti-Flk (fetal liver kinase 1) staining of a control chitosan and a chitosan heparin/VEGF
coated fiber shows little red fluorescence for the control and strong red fluorescence for
the heparin/fibronectin coated fiber, indicating high VEGF binding affinity to the chitosanheparin complex fibers.

A)

B)

Figure 3.17 Anti-Flk Staining of Chitosan/Chitosan Heparin VEGF Fibers. Anti-Flk
staining of A) control (non-coated) and B) heparin/VEGF coated fibers shows little red
fluorescence for the control and considerable fluorescence for the heparin/fibronectin
coated fiber

57
3.3.12 Phase Microscopy (MVEC Coated Chitosan Fibers)
MVEC cells are placed on chitosan fibers and images are taken thereafter to determine that
MVEC cells able to adhere to fiber and will continue to adhere to the fiber after a long
duration, i.e., 6 days. In Figure 3.18 A), two images of MVEC coated chitosan fibers after
1 day show that the cells were able to adhere. In Figure 3.18 B), two images of MVEC
coated chitosan fibers (taken on the same chitosan fibers, but different locations) shows
that cells still adhere to the fiber after 6 days.

A)

B)

Figure 3.18 Phase Images of MVEC Coated Fibers. Phase imaging of MVEC coated
chitosan fibers (coated with fibronectin, no heparin crosslinking) A) after 1 day and B)
after 6 days, shows that cells continue to remain on fibers.
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3.3.13 Live/Dead Staining (Fibers)
Live/Dead staining of RAEC coated chitosan fibronectin fibers reveals that the fiber is able
to maintain cell viability of the RAEC coated fibers after 3 days. Calcein AM/LIVE
staining in Figure 3.19 B) shows considerable green fluorescence compared to ethidium
homodimer staining in Figure 3.19 C) which shows only background red fluorescence. This
shows that the fiber is an appropriate scaffold to maintain the RAEC cells and allow for
their continued growth and migration across the entirety of the fiber.

A)

B)

C)

D)

Figure 3.19 LIVE/DEAD Images of RAEC Coated Fibers. Live/Dead Staining Imaging
of MVEC Coated Fiber at 10x magnification shows A) phase image, B) Live image, C)
Dead image, and D) Live/Dead merged image.
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3.3.14 Degradability
Images of the chitosan fiber are taken at various time points following exposure to the
enzyme. Trypan blue stained chitosan fibers without cells are used as a preliminary test to
determine when the fiber is sufficiently degraded before cell coated fibers are used. Cells
coating the fibers would affect the properties of degradation due to a combination of their
physical presence preventing the admission of acids and enzymes toward the fiber, and
excretion of metabolites which may interact with the fiber over the course of incubation.
Regardless, of this fact, this preliminary test is invaluable as the enzyme/acid bath is
harmful to the cell coated on the fiber, and so by determining the absolute minimal amount
of time necessary for fiber degradation, a greater cell viability can be had. As shown by the
images in Figure 3.20 A) and Figure 3.20 D) , the fiber does not degrade evenly, rather
parts of it degrade, while other parts remain insoluble as evident by the areas of blue that
remain. Furthermore, the phenomena of swelling occurs as shown between the images in
Figure 3.20 A) and Figure 3.20 B), in which the diameter of the fiber is shown to expand
more than 200%. Overall, although, total degradation did not occur in an organized manner,
the parts of the chitosan that did dissolve seem to have dissolved by around 30 min.
For cell coated degradation tests, the point at which the chitosan fiber is sufficiently
degraded is herein considered to be when the straight black edge of the chitosan fiber is no
longer seen. However, a difficulty with degradation is the swelling of the fiber resulting in
the construct bursting at 30 min in Figure 3.21 C) and releasing cells into the surrounding
medium at 45 min in Figure 3.21 D).
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A)

B)

C)

D)

Figure 3.20 Trypan Blue Staining of Non-Cell Coated Chitosan Fiber during
Degradation. Trypan blue stained non-cell coated fibers in HBSS pH5.5 with lysozyme
and cellulase are imaged at 4x magnification at A) 0min, B) 30min, C) 60min, and D) 90
min, showing uneven dissolution.
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A)

B)

C)

D)

Figure 3.21 Phase Imaging of Cell Coated Chitosan Fiber during Degradation.
Degradation of the chitosan fiber with the passage of time at 10x magnification show the
effect of cellulase and lysozyme on the chitosan fiber after A) 0 min, B) 15 min, C) 30
min, and D) 45 min, showing bursting after 30 min and cell ejection off scaffold.
3.3.15 LIVE/Hoechst Staining (Tube)
Live staining using Calcein AM and nucleus staining using Hoechst, reveals live cells in
green and their nucleus in blue. As can be seen in Figure 3.22, by comparing phase with
fluorescent images, almost all of the cells show green fluorescence and nucleus staining,
showing that cells were able to attach to the electrospun tube and remain viable.
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A)

B)

C)

Figure 3.22 LIVE/Hoechst Staining of Cell Coated Tube. Calcein AM and Hoechst
staining is performed on a RAEC cell coated tube at 10x magnification. A) shows phase
image, B) shows green/Live image, and C) shows blue/nucleus image. Fluorescent
coloration shows presence of cells on the tube.
3.3.16 Vascular Sprouting (Fiber/Tube)
A non-cell coated tube is embedded in Matrigel and phase images show that after six days
that no sprouts can be seen as shown by Figure 3.23. By contrast, both the tube and the
fiber after being embedded in Matrigel for six days are both able to promote vascular
sprouting are evident by the images in the Figure 3.24 and Figure 3.25.
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A)

B)

Figure 3.23 Phase Images of Non-Cell Coated Tube. Non-cell coated tube is embedded
on Matrigel and A) 10x or B) 20x magnification images are taken after 6 days, showing
absolutely no sprouting.

A)

B)

Figure 3.24 Phase Images of Vascular Sprouting from Cell Coated Fiber. Vascular
sprouting is seen emerging from the RAEC cell coated fiber after 6 days at a magnification
of 20x. A) shows sprouting angiogenesis, while B) shows maturation of the vessel by the
addition of multiple cells.

64

B)

A)

Figure 3.25 Phase Images of Vascular Sprouting from Cell Coated Tube. Vascular
sprouting is seen emerging from the RAEC cell coated tube after 6 days at a magnification
of A) 10x, showing sprouting angiogenesis, and B) 20x, showing vascular looping.
3.4 Discussion

3.4.1

Toluidine Blue Staining and FTIR

Toluidine blue staining and FTIR are used on a heparin cross-linked film to determine that
heparin has successfully been crosslinked to the chitosan. A film is used instead of a fiber
as the fiber is not large enough to provide a sample large enough for study, however, it can
be reasonably assumed that employing the same crosslinking technique on the film as the
fiber will yield the same results.
Toluidine blue is a dye that binds to sulfate groups, such as those found heparin,
but not found in chitosan. In Figure 3.7 C) and D) and Figure 3.15 B) and C), an unmodified
chitosan film and an unmodified wetspun chitosan fiber are both exposed to toluidine blue
dye, resulting in only pale/opaque coloration. In contrast to Figure 3.7 A) and B) and Figure
3.15 A) chitosan heparin film and chitosan heparin fiber are both exposed to toluidine blue
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dye and shows a blue/purple coloration. Thus, the Toluidine blue assay shows that the fiber
is successfully cross-linked with heparin.
FTIR measures absorbance of wavelength which correlate to the chemical groups
on the material. The most distinguishable chemical groups on heparin are sulfate, which
has a wavelength at 1240 nm-1 and 1040 nm-1 representing SO4 assymetric and symmetric
stretching, respectively. [80] As can be seen in Figure 3.12, there are large peaks at
wavelengths ~1200 nm-1 and ~1000 nm-1 on the heparin cross-linked chitosan film which
is similar in magnitude to powdered heparin, but is absent in the unmodified chitosan film,
showing that heparin has been successfully incorporated in the chitosan heparin film.

3.4.2

Cell Adhesion

A preliminary test using chitosan film is employed to determine the ability of cross-linked
heparin and adsorbed fibronectin to promote cell attachment. Chitosan is a natural,
biodegradable, biocompatible, and anti-bacterial material, however, lacks binding sites to
promote cell attachment. [81-83] To promote cell attachment, chitosan is chemically
modified with RGD sequences, CAG sequences, or in this study using EDC/NHS with
heparin. [72, 84-87] Heparin is a large negatively charged glycosaminoglycan which is
used to attract growth factors such as fibronectin or VEGF; which in turn help promote cell
binding. [70]
Having confirmed heparin attachment to the film via the aforementioned Toluidine
blue staining and FTIR, fibronectin is adsorbed to the chitosan heparin film. To determine
the ability of the various films to promote cell adhesion, four conditions are studied: a
control in which cells are plated on the tissue culture plate; chitosan in which cells are
plated on an unmodified chitosan film; chitosan heparin in which cells are plated on
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chitosan film covalently cross-linked with heparin, and chitosan heparin fibronectin in
which cells are plated on a chitosan film covalently cross-linked with heparin and followed
by the adsorption of fibronectin. Chitosan and chitosan heparin films show the least cell
attachment and proliferation as shown by phase and fluorescent images in Figure. 3.9 and
Figure 3.10. As stated before chitosan has no cell binding sites. As for chitosan heparin,
heparin is known to be the most negatively charged glycosaminoglycan and cells tend to
have a slight negative charge. As such the two ionically repel each other, resulting in an
initial lack of cell attachment. However, heparin also contains binding sites for VEGF, a
growth receptor present on the endothelial cells which allows for some binding. By
contrast, chitosan heparin fibronectin shows the greatest cell attachment. Fibronectin is a
glycoprotein which contains the RGD peptide sequence which promotes binding of
integrins a5b1 on endothelial cells and, thus, has the binding capabilities to allow for
greater cell attachment. [88] Furthermore, the combination of heparin and fibronectin has
been shown not only to improve cell proliferation, but to improve function of pancreatic
cells, cardiomyocytes, and sciatic nerves. [74, 89, 90]

3.4.3

Proliferation

Cell proliferation of cells grown on the four conditions was measured over three days.
Tissue culture plate (TCP) and chitosan heparin fibronectin (CHF) showed the most
proliferation, while chitosan and chitosan heparin showed the least amount of proliferation
according to the Alamar Blue assay as shown in Figure 3.11. The cell population of
chitosan and chitosan heparin initially decreased from day 0 to day 1, however the
population increased from day 1 to day 2. For day 2, chitosan heparin shows a cell
population almost rivaling that of chitosan heparin fibronectin. To explain the rebound in
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cell population it must be noted that the medium used for the endothelial cell culture
contains the growth factor VEGF. Although, the chitosan and heparin contain no binding
sites for cells, heparin can bind VEGF. Chitosan heparin contains heparin which binds to
VEGF and is used in other studies to not only promote endothelial cell attachment, but
improve cell differentiation, and capillary tube length. [75, 91]

3.4.4

Mechanical Properties

Mechanical properties of the tissue engineered scaffold can affect the properties of cells
seeded on them. For endothelial cells, high stiffness can lead to dysfunction in vivo and
expression of angiogeneic growth factors. [92-94] The measured Young’s modulus of the
chitosan fiber is 1767.7 MPa or 1.7GPa as shown by Figure 3.11. By comparison, soft
tissue has a Young’ modulus ~3kPa, collagenous bone has a Young’s modulus ~30kPa,
and a tissue culture plate/glass has a Young’s modulus >1 GPa. [95] Thus, the chitosan
fiber is highly stiff and high stiffness causes an increase in endothelial permeability and
lowered cell-cell adhesion. [96] The lowering of cell-cell adhesion presents a problem, as
will be reviewed in greater detail in the degradation section, as this would lower the burst
pressure for the endothelial cell coated fiber. Though, the high stiffness may contribute to
low burst pressure, the lowered cell-cell adhesion allows for greater angiogenesis as cells
are freed to remodel into vascular sprouts. [97] A possibility not discussed here is that the
chitosan fiber is tested when dry, however, because the chitosan fiber is experimented upon
when wet, the stiffness represented by Figure 3.12 may be erroneous as a wet fiber’s
stiffness is expected to decrease.
Another area of contention is the plastic deformation region. It is assumed by the
short strain occupied by the plastic deformation region that the material is brittle. However,
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an alternative theory for the short strain region is slip, by which the chitosan fiber in the
grips slips out.

3.4.5

VEGF Binding

To determine the ability of heparin to attach VEGF onto the fiber, immunofluorescent
staining of VEGF using Flk-1 is employed. A control/non-treated fiber and a chitosan
heparin VEGF fiber are exposed to the immunofluorescent Flk-1 antibody as shown in Fig.
3.17. The chitosan heparin VEGF conditions show considerable red fluorescence compared
to the control fiber, showing that VEGF is successfully bound to the heparin coated fiber.
Although, not used ostensibly in this model, VEGF attachment nevertheless occurs as it is
a critical component of the endothelial cell media and so can attach to both heparin and
fibronectin. More importantly, the application of VEGF to the chitosan fiber can be used
in later studies, to promote angiogenesis.

3.4.6

Cell Coating Fiber

Imaging techniques are used to determine the ability of the wetspun fibers to adequately
maintain cell adhesion and viability of cells coated on them. Phase imaging, as shown in
Figure 3.18 A) and B) reveal that the cells are able to adhere onto the wetspun fiber after
one day and remain even after six days. Furthermore, as shown by Figure 3.18 B),
endothelial cells show a parallel and cobblestone morphology similar to that seen in vivo.
[98] More importantly, after six days most of the fiber is covered by the cells and, thus, a
non-fenestrated tissue engineered construct following degradation of the chitosan should
be produced. A Live/Dead cell staining of the wetspun fibers, as shown by Figure 3.19,
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reveals that most of the cells remaining on the fiber are green/Live and few red/Dead,
showing that the scaffold is able to maintain cell viability.
The purpose of this cell coating is to create a tissue engineered blood vessel which
will undergo angiogenesis and connect with the spheroid, much as angiogenesis occurs
between blood vessels and solid tumor in vivo. To show that angiogenesis occurs, phase
images are taken of the cell coated fiber and tube after embedding on Matrigel. For the cell
coated fiber, sprouting angiogenesis can be seen in Figure 3.23 A), and vascular looping in
which vascular sprouts combine can be seen in Figure 3.23 B). Thus, the cell coated fiber
has successfully promoted angiogenesis.
Despite, the success seen in promoting sprouting angiogenesis and vascular
looping, vascular sprouts fail to mature as they appear not to contain lumens.

3.4.7

Degradation

The purpose of the blood vessel is to provide a conduit for blood to flow. Thus, the most
important feature of the tissue engineered blood vessel is the presence of a hollow lumen.
Although, this study is more concerned with using the tissue engineered blood vessel to
distribute anti-cancer drugs, the importance of the feature remains the same. This tissue
engineered blood vessel differs from other such constructs in that the scaffold is only
employed to give shape to the cells and afterwards is removed allowing for the construction
of a discrete tissue engineered blood vessel. Cells are coated on a chitosan fiber and cells
are allowed to grow and take the shape of a vessel. After which, the chitosan fiber is
removed or cored. In order to core the chitosan, a combination of acidic and enzymatic
degradation is employed.
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Manual removal of the chitosan is difficult because of the minute nature of the
tissue engineered blood vessel and because the chitosan scaffold and cells have an affinity
for one another meaning that removal of the chitosan will also remove many of the cells.
Chemical removal via acidic and enzymatic degradation is employed instead. The first
technique to chemically remove chitosan is via acidic degradation. As mentioned
previously, chitosan dissolves below a pH 7.3 and a precipates above the value, and so by
exposing the solid chitosan fiber to an acidic environment, the fiber will dissolve into a
liquid and out of the construct. The second technique to chemically remove the chitosan is
via enzymatic degradation. Enzymes have the ability to degrade specific materials with an
extremely high affinity. Chitosanase or chitinase, therefore would be the most likely
candidate with which to degrade chitosan, however the enzyme is cost prohibitive. This
does not necessarily preclude the use of enzymes to degrade the chitosan as other enzymes
such as cellulase can have nearly the same effectiveness at degrading the material. [76, 99]
In this case, it is hypothesized that the enzyme cellulase degrades chitosan as both chitosan
and cellulase have the β 1,4-glycosidic linkage between monomers.[99]
When fibers are exposed to pH 5.5 with 12.5mg/mL cellulase, the chitosan fiber
begins to degrade. To assess when the chitosan fiber has completely degraded a variety of
techniques are employed including: trypan blue staining, and phase morphology.
The use of trypan blue to determine when the chitosan has degraded obviates from
the usual use of the dye, as the dye is used to stain dead cells blue. In this case, trypan blue
has an affinity for positively charged materials such as chitosan and so stains the outline of
the chitosan fiber in blue as exhibited by Figure 3.20. When this trypan blue dyed fiber is
exposed to acidic/enzymatic degradation conditions, the fiber swells as shown in Figure
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3.20 A) and B). The reason for this is that the fiber can be considered a hydrogel. When in
an acidic solution, the amide groups will obtain a positive charge resulting in electrostatic
repulsion between the polymers of chitosan. The resulting network of polymers will allow
the free flow of H2O into the network, forming a hydrogel and causing the structure to
swell with H2O.
A simpler method to determine degradation is observation under microscope. The
generality that straight/smooth lines don’t exist in nature also applies in this study as the
manufactured fiber, even when encased in cells, still has a straight/smooth outline. Thus,
once the straight/smooth line is no longer seen, it can be assumed that the manufactured
fiber has been sufficiently dissolved.
There are limitations to using chemical degradation to core the chitosan fiber as the
cells in the construct must remain viable and the construct must remain intact. For acidic
degradation, a pH of 6 is used and no lower due to concerns over cell viability in a low pH
environment. The medium used to expose the cell coated fiber is Hank’s Buffered Saline
Solution (HBSS) due to the nutrients present to keep the cells viable and the calcium
present to maintain the cell-cell contacts with which to keep the construct intact. When the
cell coated fiber is exposed to the acid, it swells. This swelling has the ability to break the
cell-cell contacts which results in the destruction of the construct. In order to reduce this,
the construct must resist the outward force of the swelling. What is more swelling is not
consistent as only part of the construct burst, while the remainder remained intact as shown
by Figure 3.21 C).
As such the fiber cannot be hollowed at present time. Since, the fiber is not
hollowed successfully and so any experiments to determine cell viability following acid
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and enzymatic treatment are not performed. Solutions to the problem could be the inclusion
of additional cell types, most notably smooth muscle cells and fibroblasts. Circumferential
and longitudinal strength in the blood vessel lies within the tunica media and tunica
adventitia, the middle and outer layers of the blood vessel. Within the tunica media are
smooth muscle cells where most of the circumferential strength lies and within the tunica
adventitia are fibroblasts where most of the longitudinal strength lies. [100] By including
one or both cell types onto the endothelial cell coated tube, additional strength could be
rendered to oppose the outward swelling force.

3.4.8

Cell Coated Tube

As an alternative to the fiber, a cell coated tube is proposed. The tube is constructed by
wrapping a chitosan electrospun mat around a 22 gauge syringe needle, neutralizing the
mat with NaOH, followed by washing, and drying. After removal from the needle, the tube
is processed in the same manner as the fiber in order to crosslink the structure and coated
it was cells. It must be noted that unlike the fiber, the size of the tube is much larger and,
thus, cannot recapitulate the diameter of the blood vessel in vivo. Although, this would
alter the fluid dynamics of flow within the tissue engineered blood vessel, this project
employs the tissue engineered blood vessel solely as a means of delivery and such an
enlarged diameter should not present a problem.
To ensure that such a construct could support the viability of cells presented on it,
cells on electrospun tubes are visualized using Live/Calcein and Hoechst/nucleus staining.
Phase imagery is unable to determine presence of cells on the electrospun tube due to the
non-transparent nature of the chitosan electrospun mat. As such fluorescent imagery must
be used to visualize the cells instead, however, not red fluorescence such as that emitted
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by ethidium homodimer as the chitosan electrospun mat is autofluorescent for the color
red. The results of this experiment as shown in Figure 3.22, show numerous nuclei on the
surface of the tube in Figure 3.22 C), proving that the tube allows for cell coating, and the
equally numerous green stained cells shows that the tube is able to maintain cell viability
in Figure 3.22 B).
To determine the ability of such a construct to promote angiogenesis, a cell coated
tube is embedded on Matrigel. After a week of incubation in the Matrigel, vascular sprouts
can be seen along the sides of the vascular construct, as shown in Figure 3.24, thus, showing
that such a construct can support angiogenesis. The early steps of angiogenesis are evident
as seen in Figure 3.24 A), in which tiny finger-like protrusion can be seen emerging from
the vessel bed. Further steps in angiogenesis are seen in Figure 3.24 B), in which the ends
of the vascular sprouts combine together to form a vascular loop.
Although, early steps in angiogenesis can be witnessed in such a model, the
vascular sprouts never form mature lumens. This can be remedied in the future by the
inclusion of a second coating of fibroblast cells or the introduction of flow through the
tube. [101-104] In order to stabilize the vascular sprouts, mural cells are required to interact
with the endothelial cells. The most notable of these is the pericyte, as mentioned
previously, however in vivo and in vitro it is also known that the fibroblast can also serve
to stabilize the structure and can aid in the vascularization of the spheroid. [105, 106]
Hence, a second cell coating of fibroblasts done in a similar manner to that of the first
coating of endothelial cells, should be able to promote the mature vascularization of the
cell coated tube. Another manner to promote mature vascularization is the introduction of
flow inside the tube. Although the mechanism by which flow promotes vascularization is
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unknown, the presence of flow is known to promote maturation of vessels in vitro, as well
as in wound healing and development.

CHAPTER 4
VASCULARIZED CANCER MODEL

Aim 3 is to construct a biomimetic and vascularized liver cancer model, in which
multicellular cancer spheroids and chitosan-heparin micro/nanofiber scaffolds seeded
with endothelial cells are combined .recapitulating tumor angiogenesis such that a
vasculature is formed to allow passage of a drug into the spheroid. . We hypothesize that
this model can be used to characterize the effect of drugs on vascular sprouts, anastomosis,
migration, and transportation of drugs through cancer.

4.1 Background
As mentioned previously, anti-angiogenic drugs have failed alone as a cancer treatment,
however, co-administration with chemotherapy drugs has been shown to greatly improve
clinical outcomes. [5, 6, 107, 108] Thus, co-administration has breathed new life into antiangiogenic drug therapies, but at the same time has illuminated a problem with cancer
research: in vitro versus clinical results.
Clinical results should be predicted during the initial phases of drug testing,
however, aren’t and can be blamed on broad assumptions. The drug testing process, in
brief, begins with in vitro testing, followed by animal studies, and finally followed by
clinical trials. Clinical trials are the most expensive phase of drug testing and most telling
as human beings, for which these drugs are being tested for, are being tested upon.
However, because of their cost/ethical considerations, clinical trials are usually reserved
later in the process in hopes that in vitro and/or animal testing will root out those drugs that
are dangerous and/or ineffective. But sometimes, these hopes are misplaced as it is possible
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that in vitro and/or animal testing will deem a drug safe/effectual that is later determined
by clinical trials as dangerous/ineffective. An equally valid scenario is the opposite, when
in vitro and/or animal testing will deem a drug unsafe/ineffective, when clinical trials show
the drug to be safe/effectual. In either case, the disparity between the results of in vitro
and/or animal testing with that of clinical trials can be blamed on broad assumptions made
during the course of in vitro and/or animal testing, however, as mentioned in the
introduction, this is not the case.
Nowhere is the contradiction between in vitro and clinical results more noticeable
than in Manov et al. and Abou-Alfa et al. In clinical trials performed by Abou-Alfa et al.,
co-administration of sorafenib and doxorubicin shows a mean overall survival of the
patients of 13 months compared to 3 months when sorafenib is administered alone. [109]
In an in vitro experiment performed by Manov et al., co-administration of sorafenib and
doxorubicin in a Hep3B/HepG2 model, showed an increase in cell viability. [110] The
results of this in vitro experiment run counter to clinical results, however, can be explained
by the molecular mechanisms by which each drug causes apoptosis. Doxorubicin can cause
apoptosis via the sustained upregulation of the MAPK/ERK pathway. [111] Sorafenib can
cause apoptosis via the downregulation of the MAPK/ERK pathway via B-Raf blockage.
[6, 112] Thus, the two drugs counteract each other. Sorafenib, though, has other means by
which to cause apoptosis, namely via the anti-angiogenic strategy in which
hypoxia/ischemia induces apoptosis. In the model system devised in Manov et al., hypoxia
is lacking as it is a 2D monoculture and so the culture is always sufficiently oxygenated.
Admittedly, Manov et al. noted this fault in the model and are justified in that the purpose
of their experiment was to investigate the effects of these two drugs and their counteracting
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mechanism. However, if the purpose of such a model is not to determine the effect of
molecular mechanisms and instead is used for in vitro drug testing, then this in vitro model
would predict co-administration of doxorubicin and sorafenib to be ineffectual. In order
to address the problems involved in in vitro testing, a new model must be constructed that
incorporates various aspects of cancer including vasculature and hypoxia into its design.
Hypoxia is an important aspect that needs to be incorporated into an in vitro
model’s design and is difficult to recreate in a 2D model, thus, requiring a 3D model. The
effect of hypoxia on cancer has become a focus of research in recent years due to the wide
range of effects hypoxia has on cancer. Through a series of mutations, a cell begins to grow
uncontrollably and forms the nascent tumor. [1, 113] Initially, simple diffusion is able to
transport nutrients and gases throughout the nascent tumor. However, when the tumor
reaches the size of ~1 mm3, transport of nutrients and gases via simple diffusion is no
longer possible resulting in a hypoxic/necrotic core within the tumor. [2, 114] The hypoxic
conditions results in the modulation of various signal transduction pathways. Under the
normal conditions of oxia, the transcription factor HIFa interacts with Von Hippel Landau
(VHL) factor and becomes ubiquitylated for proteosomal degradation. However, during
hypoxia HIFa is transported into the nucleus where it dimerizes with HIFb, interacts with
hypoxia related elements (HRE), and transcribes tumor angiogenic factors. [11, 13, 115118] Specifically, VEGF is transcribed which causes sprouting angiogenesis to relieve
hypoxia in the affected area. When, anti-angiogenic drugs are used to halt the angiogenesis
process, critical nutrients and oxygen are deprived from the tumor resulting in tumor
starvation and hypoxia which leads to tumor necrosis. [12, 119, 120] The tumor
hypoxia/ischemia brought on as a result of anti-angiogenic drug exposure is evident in
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clinical and in vivo studies, however, is absent in Manov et al., thus explaining why a
combination of sorafenib and doxorubicin showed growth instead of cell population
decline.
However, the hypoxia following exposure to the anti-angiogenic drug leads to drug
resistance. Hypoxia leads to the stabilization of HIF-a, which is able to dimerize with HIFb and forms a complex which activates gene expression. [11, 13, 115] Most notable of the
genes expressed is MDR-1 which transcribes the drug efflux protein P-gp. Also, hypoxia
can lead to acquired drug resistance, when the hypoxia leads to the upregulation of
alternative pro-angiogenic signals pathways such as PI3K/Akt. [6, 108] Overall, hypoxia
leads to drug resistance and an accurate model should mimic both the initial decrease in
viability due to tumor starvation/hypoxia and the drug resistance due to the hypoxia
resulting from exposure to the anti-angiogenic drugs.
To mimic tumor angiogenesis and hypoxia, a biomimetic and vascularized liver
cancer model is fabricated in which multicellular cancer spheroids and chitosan-heparin
micro/nanofiber scaffolds seeded with endothelial cells are combined together on Matrigel
.recapitulating tumor angiogenesis such that a vasculature is formed to allow passage of
a drug into the spheroid.
Due to the abnormal growth of cancer and the failure of angiogenesis to meet the
oxygen/nutrient needs of the growing cancer, differential regions of oxia and hypoxia are
created within the tumor. A spheroid is able to mimic these differential regions of oxia and
hypoxia given its geometry; in which cells on the outer layer cells are exposed to oxygen
and nutrients, while those cells of the interior fail to receive oxygen and nutrients. Liver
cancer is known to be highly vascularized, thus, in order to create a highly vascularized
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model, the spheroid’s ability to create a region of hypoxia is taken advantage of. The
hypoxic/necrotic core of the spheroid causes the upregulation of a variety of tumor
associated factors, specifically VEGF. Local blood vessels react by undergoing
remodeling, in which the basement membrane of the vessel disintegrates, endothelial cell
junctions dissolve, and the endothelial cells remodel to form a vascular sprout. [121, 122]
The vascular sprout will grow along the chemotactic gradient of tumor angiogenic factors
toward the source of hypoxia/tumor and proceed to form blood vessels in the region until
oxia is restored.
Ideally, such a model would be able to mimic the path an anti-angiogenic drug takes
from the bloodstream through the tumor vasculature and into the tumor. Our model should
accomplish this as the hypoxia derived from the spheroid’s geometry is like the solid tumor
and will cause vascular sprouting and angiogenesis from the endothelial cells coating the
cell coated tube which will proceed to form a vasculature with the spheroid. Angiogenesis
should bridge the spheroid and the cell coated tube, and would be able to allow the passage
of drugs into the spheroid. Part of this tumor vasculature is exhibited in the previous section
in which vascular sprouts are seen emerging from the cell coated tube and would ideally
vascularize the spheroid. However, that takes time and due to the limited lifespan of in
vitro models it is not possible for vascular sprouts from the cell coated tube to vascularize
the spheroid. Thus, the spheroids must be pre-vascularized and form their own vascular
sprouts which can anastomize with the vascular sprouts and bridge the cell coated tube
with the spheroid. To pre-vascularize the spheroids, endothelial cells are added to the cell
media used in forming the hanging droplets to create triculture spheroids made of HepG2,
fibroblast, and endothelial cells.
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Ostensibly, a model of cancer angiogenesis would minimally require the cancer
cells in question and endothelial cells, however, fibroblasts aid in cell survival and to
promote vascular sprouting. In regards to angiogenesis, fibroblasts provide soluble growth
factors such as VEGF and interact with endothelial cells to promote vascular sprouting and
networking. [67, 101, 123-127] Besides, producing vascular sprouts, endothelial cells,
much like fibroblasts, can improve urea metabolism, albumin metabolism, and bile
canaliculi/CLF staining of HepG2 cells co-cultured with it. [22, 128-132]
To aid in the formation of vascular sprouts to form from the triculture spheroids,
the triculture spheroids will be cultured on Matrigel. Matrigel is collagen IV and other
extracellular matrix components derived from the Engelbreth-Holm-Swarm (EHS) mouse
sarcoma and promotes the vascularization of endothelial cells. Hence when endothelial
cells are cultivated in heterospheroids on Matrigel, the endothelial cells will form vascular
sprouts that emanate from the spheroid, much like how vascular sprouts would emanate
from the aortic ring in the aortic ring assay. Anti-angiogenic drugs affects angiogenesis,
preventing vascular sprout growth. Thus, when our model is exposed to an anti-angiogenic
drug, the vascular sprouts will stop growing or even regress and so the model can be used
to assess the anti-angiogenic capability of a drug. For this study, the anti-angiogenic drug
sorafenib is used. Sorafenib/Nexavar blocks VEGF and PDGF receptors, prevent HIFa and
VEGFa expression, and block the Raf/MEK/ERK signal transduction pathway. [6, 133,
134]
Vascular regression is the remodeling and pruning of the vasculature as a result of
drug exposure as mentioned previously, or naturally. The natural occurrence of vascular
regression would affect this model by causing vascular sprouts to retract before they can
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anastomize with each other and/or form lumens. The presence of fibroblasts and paracrine
factors elicited by the fibroblasts is able to stabilize the vascular sprout by expressing the
pro-stabilization factor Ang-1. [135] Given presence of fibroblasts in our model, the
vascular sprouts should be able to remain stable and grow overall in the absence of drugs.
Furthermore, due to the unregulated expression of VEGF and other growth factors, and
irregular oxygen supply in cancer, it is a question whether vascular regression even occurs
in cancer. [136] Thus, natural vascular regression should not present a problem for the
vascular sprouting assay.
Besides physically connecting spheroids and cell coated tube, the model must also
prove itself perfusable, such that an anti-angiogenic drug can travel from the tube into the
spheroid. In animal studies proving that an implanted model is perfusable requires a simple
injection of a fluorescent dye into the bloodstream. If the implanted model has connected
with the surrounding native vasculature and if the vasculature within the model contains a
lumen, then upon dissection of the animal, the fluorescent dye should be revealed within
the model’s vasculature network. An in vitro model does not have the same option as it is
difficult, using tools available to the common laboratory, to inject fluorescent dye into such
a system due to the diminutive size of the vasculature and a lack of a point of entry. The
cell coated tube abrogates this problem as the cell coated tube is large enough such that a
pipette is able to inject fluorescent compounds inside.
As an additional experiment, the triculture spheroid on Matrigel can be used as an
alternative to the rat/mouse aortic ring assay. Assays of the effect of an anti-angiogenic
drug on endothelial cells usually employ the rat/mouse aortic ring assay, an in vitro assay
in which an aortic ring is excised from the organism and grown on Matrigel with or without
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the vehicle, followed by the measurement of the length or area of the vascular sprouts.
[137] Although, the aortic ring assay is the standard model, it is not without problems. The
aortic ring assay measures the effect of a vehicle on rodent endothelial cells, which may or
may not be similar to human endothelial cells. Also, the aortic ring assay may lack
consistency as the population of cell types may differ due to the variation inherent amongst
specimens. Even the sex of the rodent may effect angiogenesis as male specimens are more
angiogenic than female specimens. The most notable problem with the aortic ring assay,
especially when used to measure the effect of anti-angiogenic cancer drugs is the fact that
the aortic ring is an aortic ring without the presence of cancer cells. Cancer cells are critical
to the process of tumor angiogenesis and have been shown in vitro to aid in the process of
angiogenesis and vascularization in vitro due to cell-cell contact and/or release of growth
factors. [78, 138-140] More importantly, endothelial cells can interact with the cancer cells
altering the metabolism of cultures reacting various drugs. [141] To remedy some of the
problems inherent with the aortic ring assay, an alternative model is proposed by
incorporating endothelial cells into our previous heterospheroid model of cancer. Such a
model would be an improvement over the aortic ring model in that 1) each spheroid would
have a consistent population of cells relevant to cancer angiogenesis, 2) wouldn’t require
the use of animal models or surgical procedures to remove the aortic ring, and 3) include
cancer cells to provide cues for angiogenic growth.
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4.2 Methods
4.2.1 Culture (HUVEC)
Human umbililcal vascular endothelial cells (HUVEC; ; a gift Dr. Eun J. Lee’s lab) are
cultured in endothelial cell growth medium (EGM-2 Bulletkit Lonza) containing basic
fibroblast growth factor (bFGF), EGF, insulin-like growth factor-1 (IGF-1), VEGF,
hydrocortisone, ascorbic acid, heparin, gentamicin, and amphotericin-B. All cultures are
incubated in 10% CO2, 37oC incubator.

4.2.2

Hanging Drop Method-Triculture Spheroid

Triculture spheroids are fabricated using the hanging drop method, as described previously
in Section 2.2.2. To obtain triculture spheroids, 1,000 HepG2, 1,000 growth arrested 3T3J2 fibroblast cells, and 1,000 endothelial cell (RAEC or HUVEC) in 30 L droplets,
containing RAEC or HUVEC media depending on endothelial cells used, are plated on a
100 mm Petri dish and inverted. Spheroids are harvested after 7 days.

4.2.3

Vascular Sprouting (Length)

When cultured in spheroids and grown on Matrigel, endothelial cells have the potential to
form vascular sprouts. The length of these sprouts can be used to assay the effect of various
drugs on the vascularization of a tumor. The spheroids are incubated on the surface of
Matrigel and sprouting is allowed to occur over the course of 7 days. The spheroids are
then exposed to various concentrations of a drug (sorafenib: 0M, 5M, and 10M).
Images are taken at 10x magnification and length of sprouts analyzed using SigmaScan
Pro5.
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4.2.3

Vascular Sprouting (Immunohistochemistry)

To ensure that the vascular sprouts are indeed the product of endothelial cell induced
angiogenesis and not one of the other cell types masquerading as vascular sprouts, such
vascular sprouts are stained for CD31, an antibody pertinent to endothelial cells. Triculture
spheroids are harvested after 7 days. Collagen gel (1.2 mg/mL) and 10x DMEM is allowed
to gel at 37oC for 30 min and spheroids are embedded on top of the gel. Sprouts are allowed
to grow on the collagen gel surface for another 7 days. The culture is then fixed with 4%
paraformaldehyde for 10 min before being stained with FITC mouse anti-human CD31
(BD Pharmingen) (1:50) in PBS overnight at 4oC.

A)

B)

C)

Figure 4.1
Design of Vascularized Model. Design of vascularized model is featured
showing the fabrication of the model, starting with A) the embedding of both spheroids
and vascular tube on Matrigel, B) spheroid and vascular tube forming vascular sprouts,
and C) the addition of a second layer of Matrigel.

85
4.2.5

Anastomosis

Vascular sprouting is shown to independently occur in the triculture spheroids and the cell
coated tube. When placed together in the same culture, it is possible for these vascular
sprouts emanating from the triculture spheroid and cell coated tube to interact with each
other in what is known as anastomosis. To record this event, triculture spheroids and cell
coated tube are embedded together on Matrigel and monitored over the course of time for
interactions between the vascular sprouts.

4.2.6

Migration

Migration of spheroids toward the fiber/tube is evident in some circumstances. By taking
images at various time intervals, the migration can be monitored.

4.2.7

Fluorescent Dextran/Doxorubicin Injection

To prove that vascular sprouts of the spheroid and the cell coated tube have anastomized
and formed a lumen, FITC dextran (70kDa) or doxorubicin is injected into the cell coated
tube. If a lumen is formed between the cell coated tube and spheroid, and no physical
leakage has occurred, then fluorescent dextran/doxorubicin should only be viewed in the
regions of the cell tube, the vasculature between the tube and the spheroid, and within the
spheroid itself. Note, doxorubicin, as well as being a chemotherapy drug, is slightly
fluorescent for the color red and, thus, can be used to show the distribution of the drug
throughout the model.
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4.3. Results

4.3.1

Vascular Sprout (Drug Testing)

Images of vascular sprouts emanating from the spheroid were taken and length of sprouts
are measured by SigmaScan Pro5. For all conditions the vascular sprouts in the
0uM/control condition showed continued sprout length growth. In contrast, vascular
sprouts in drug exposed (5M and 10M conditions) show a decrease sprout length
growth. For the 10M condition, there cease to be any vascular sprouts present by day 4.
There is a significant difference (n=10, **p<0.005) between the 0M/control and the drug
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exposed conditions for each of the following days.

300

Triculture Spheroid (HUVEC) Vascular Sprout Length
Exposed to Anti-Angiogenic Drug Sorafenib

250

200
150
100

**
**

50

**
**

**
**

0
0

1

2
0uM Day

**
**
4

5

**
**

7

5uM

10uM

Figure 4.2
Triculture Spheroid (HUVEC) Vascular Sprout Length Exposed to AntiAngiogenic Drug Sorafenib. Lengths of the vascular sprouts in HUVEC triculture
spheroid when exposed to sorafenib shows for 0M/control condition increased growth,
whereas 5M and 10M conditions shows decreased growth. Sprout length is normalized
to day 0 average before drug treatment. Values represent averages ± SD (n=10, *P<0.05,
** P<0.005, when comparing 5 μM and 10 μM to 0 μM.
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Figure 4.3
Phase Images of Triculture (HUVEC) Spheroids and Vascular Sprouts
Exposed to Sorafenib. Images of vascular sprouts from HUVEC triculture spheroids
show vascular sprouts before and after exposure to drugs on day 1 an day 4. A) shows the
0M/control, and B) shows the control after 4 days revealing increased growth. C) shows
the before and D) shows the after image of HUVEC triculture spheroids exposed to 5M
sorafenib. E) shows the before and F) shows the after image of HUVEC triculture
spheroids exposed to 10M sorafenib. Greater concentration of sorafenib shows greater
decrease of sprout length.
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Triculture (RAEC) Spheroid Vascular Sprout Length
Exposed to Cytotoxic Drug Doxorubicin
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Figure 4.4
Triculture Spheroid (RAEC) Vascular Sprout Length Exposed to
Cytotoxic Drug Doxorubicin. Length of the vascular sprouts in RAEC triculture spheroid
when exposed to sorafenib shows for 0M/control condition increased growth whereas
5M and 10M conditions shows decreased growth. Sprout length is normalized to day 0
average before drug treatment. Values represent averages ± SD (n=10, *P<0.05, **
P<0.005), when comparing 5 μM and 10 μM to 0 μM.
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Triculture (RAEC) Spheroid Vascular Sprout Length
Exposed to Anti-Angiogenic Drug Sorafenib
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Figure 4.5
Triculture Spheroid (RAEC) Vascular Sprout Length Exposed to AntiAngiogenic Drug Sorafenib. Length of the vascular sprouts in RAEC triculture spheroid
when exposed to doxorubicin shows for 0M/control condition increased growth whereas
5M and 10M conditions shows decreased growth. Sprout length is normalized to day 0
average before drug treatment. Values represent averages ± SD (n=10, *P<0.05, **
P<0.005), when comparing 5 μM and 10 μM to 0 μM.
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Figure 4.6
Phase Images of Triculture (RAEC) Spheroids and Vascular Sprouts
Exposed to Sorafenib. Images of vascular sprouts from RAEC triculture spheroids show
vascular sprouts before and after exposure to drugs on day 1 and day 4. A) shows the
control, and B) shows the control after 4 days revealing increased growth. C) shows the
before and D) shows the after image of RAEC triculture spheroids exposed to 5M
sorafenib. E) shows the before and F) shows the after image of RAEC triculture
spheroids exposed to 10M sorafenib. Greater concentration of sorafenib shows greater
decrease of sprout length.
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Figure 4.7
Phase Images of Triculture (HUVEC) Spheroids and Vascular Sprouts
Exposed to Doxorubicin. Images of vascular sprouts from RAEC triculture spheroids
show vascular sprouts before and after exposure to drugs on day 1 and day 4. A) shows
the before and B) shows the after image of RAEC triculture spheroids exposed to 10M
sorafenib. C) shows the before and D) shows the after image of RAEC triculture
spheroids exposed to 5M doxorubicin. E) shows the before and F) shows the after image
of RAEC triculture spheroids exposed to 10M doxorubicin. Greater concentration of
doxorubicin shows greater decrease of sprout length.
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4.3.2 Vascular Sprout (Immunohistochemistry)

CD31 staining of the triculture spheroids containing HUVEC cultured on Matrigel
fluoresces for endothelial cells. On what is presumed to be the vascular sprouts, a majority
of the cells fluoresce and therefore can be assumed to be endothelial cells. Non-green
fluorescing cells are present alongside the endothelial cells on the vascular sprouts as
evident by DAPI stained images.

A)

B)

C)

Figure 4.8
CD31 and DAPI Images of Triculture (HUVEC) Spheroids and Vascular
Sprouts. Vascular sprouts radiating from HUVEC triculture spheroids on collagen gel are
visualized at 20x magnification. A) shows phase image, B) shows CD31 stained image,
and C) shows DAPI stained image, showing the presence of endothelial cells.
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4.3.3 Vascular Sprout (Live/Dead)

Images of triculture spheroids show Live/Dead imaging after the addition of 10M
doxorubicin or 10M sorafenib. Following exposure to either drug, spheroids show
considerable red fluorescence or cell death.

A)

B)

C)

D)

Figure 4.9
LIVE/DEAD Assay of Triculture (RAEC) Spheroids following Exposure
to Doxorubicin. RAEC triculture spheroids are exposed to anti-cancer drugs and images
are taken at 10x magnification. 10 M doxorubicin exposed conditions are shown in the
first four images. A) shows the phase image, B) shows the live image, C) shows the dead
image, and D) shows live/dead image. Considerable red fluorescence compared to green
fluorescence shows that doxorubicin has caused apoptosis.
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A)

B)

C)

D)

Figure 4.10 LIVE/DEAD Assay of Triculture (RAEC) Spheroids following Exposure
to Sorafenib. RAEC triculture spheroids are exposed to anti-cancer drugs and images are
taken at 10x magnification. 10M sorafenib exposed conditions are shown in the last four
images. A) shows the phase image, B) shows the live image, C) shows the dead image,
and D) shows the live/dead image. Considerable red fluorescence compared to green
fluorescence shows that sorafenib has caused apoptosis.

4.3.4

Anastomosis

Anastomosis is seen occurring between vascular sprouts of the triculture spheroids and the
vascular sprouts of the cell coated fiber/tube. Over the course of time, vascular sprouts can
be seen independently manifesting from the triculture spheroid and cell coated fiber/tube,
until the multiple sprouts are seen conjoining with one another. Conjoined vascular sprouts
can be seen as enlarged compared to the size of singular sprouts.
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A)

B)

C)

D)

E)

Figure 4.11 Anastomosis Between Cell Coated Fiber and Triculture Spheroid.
Anastomosis between spheroid and cell coated fiber can be seen at 10x magnification after
day A) 1, B) 2, C) 3, D) 5, and E) 7 embedding on Matrigel. Vascular sprouts deriving
from the spheroid and the cell coated fiber can be seen interacting with one another.
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A)

B)

Figure 4.12 Anastomosis Between Cell Coated Tube and Triculture Spheroid.
Anastomosis between spheroid and cell coated tube can be seen at A) 10x and B) 20x
magnification after day 6.
4.3.5

Migration

10x phase images of single spheroid and fiber is monitored over the course of several days
and shown in Figure. 4.13. As can be seen the spheroid is able to migrate closer to the fiber
moving approximately 100 M distance. 10x phase images of a single spheroid and tube
is monitored over the course of several days and shown in Figure. 4.14. As can be seen,
the spheroid is able to migrate onto the tube after 14 days, after which the spheroid loses
shape and melds with the tube.
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A)

B)

Figure 4.13 Migration of Triculture Spheroid to Cell Coated Fiber. Migration of
HUVEC triculture spheroid toward cell coated fiber can be seen on A) 1 day and B) 3
days, after embedding on Matrigel, showing the spheroid moving closer to the fiber.
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A)

B)

C)

D)

Figure 4.14 Migration of Triculture Spheroid to Cell Coated Tube. Migration of
HUVEC triculture spheroid toward cell coated tube can be seen on A) 1 day, B) 3 days,
C) 7 days, and D) 14 days after embedding on Matrigel, showing the spheroid merging
with the tube.
4.3.6

Fluorescent Dextran Injection

10x images of an area including spheroid and tube shows the distribution of fluorescent
dextran within the region. Images are that of the region 10 min after injection of the FITC
dextran into the cavity of the tube. Failure of green fluorescence to appear solely in the
lumen of the cell coated tube, spheroid, and vasculature shows some non-specific diffusion,
which is expected. Some fluorescence can be seen with the vascular sprouts showing the
emergence of a nascent lumen. However, these vascular sprouts are not seen in the area of
the spheroid.
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A)

B)

C)

Figure 4.15 Images of Vascularized Cancer Model Following Injection of FITC
Dextran. Injection of FITC dextran can be seen at 10x magnification. A) shows phase
image, B) shows green fluorescent image before injection of FITC dextran, and C) shows
green fluorescent image 10 min after injection of FITC dextran. Green fluorescence can
be seen in region of vascular sprouts.
4.3.7

Doxorubicin Injection

10x images of an area including spheroid and tube shows distribution of doxorubicin within
the region. Images are that of the region 10 min after injection of doxorubicin into the
cavity of the tube. Like fluorescent dextran, doxorubicin, evident by red fluorescence, can
be seen throughout the model. Red fluorescence can be seen within the spheroid, however,
none can be seen in the vascular sprouts.
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A)

B)

C)

Figure 4.16 Images of Vascularized Cancer Model Following Injection of
Doxorubicin. Injection of doxorubicin can be seen at 10x magnification. A) shows phase
image, B) shows red fluorescent image before injection of doxorubicin, and C) shows red
fluorescent image 10 min after injection of doxorubicin. Red fluorescence can be seen in
spheroid region.
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4.4 Discussion
4.4.1 Model Overview
When the cell coated electrospun tube is embedded on Matrigel with triculture spheroids,
three scenarios occur between the tissue engineered blood vessel and the spheroids. The
first scenario is that the tissue engineered blood vessel and spheroids do not interact. The
second scenario is anastomosis in which sprouting angiogenesis occurs between the
spheroid and tissue engineered blood vessel, resulting in the interaction between the
vascular tips. The third scenario is migration in which the spheroids migrate toward the
tissue engineered blood vessel. All three scenarios occur with varying degrees within the
model and mimic cancer within the human body.

4.4.2 Vascular Sprout Assay
Triculture spheroids formed from HepG2, fibroblast, and endothelial cells are embedded
on Matrigel and are allowed to sprout before exposure to anti-cancer drugs. Such a model
can be used as an alternative to the rat aortic ring assay and to test this, the lengths of the
vascular sprouts are measured at different time points and with different concentrations of
drugs. Two types of triculture spheroids are tested, those which contain the endothelial cell
type RAEC and those that contained the endothelial cell type HUVEC. RAEC are used in
this circumstance to help compare the triculture spheroid with the rat aortic ring assay.
HUVEC are used in this circumstance to help connect the vasculature of the spheroid with
that of the cell coated tube. In the future, triculture spheroids should contain all human cells
in order to not only connect the vasculature of the spheroid with the cell coated tube, but
provide an in vitro human cell assay alternative to the rat aortic ring assay.
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In the rat aortic ring assay, a rat aorta is exposed to a vehicle and the length or area
of the vascular sprouting is measured. In order to validate our model, vascular sprouting is
also measured after exposure to a vehicle. In this case, our model is the triculture spheroid
on Matrigel, and our vehicle are the drugs sorafenib and doxorubicin. As shown by Figure.
4.8, sprouts are seen emerging from the spheroid and stain for CD31 confirming the sprouts
as endothelial in origin. However, no negative control was performed to determine whether
these sprouts autofluoresce for color green as a sign of CD31 expression. In our model it
is assumed that the vascular sprouts are the product of endothelial remodeling to form stalk
and tip cells, rather than fibroblasts expanding. In order to determine whether these sprouts
are endothelial or fibroblast cells, a negative control should have been performed in which
heterospheroids are incubated on Matrigel to determine if similar sprouting can be seen.
Given that the fibroblasts have been treated with mitomycin C to arrest growth and that
vascular sprouts can be seen stained for CD31 as evident by Figure 4.8, it can be assumed
that vascular sprouts are the product of endothelial cell remodeling. In the future, to further
verify the identity of these sprouts, GFP-HUVEC can be used and if green fluorescence is
witnessed in the region of the sprouts, prove the presence of endothelial cells.
When RAEC triculture spheroids are exposed to doxorubicin and sorafenib, the
vascular sprouts in the vehicle conditions decrease, while the control condition continues
to increase. Comparing the drug efficiency based on vascular sprouts shows that
doxorubicin showed a greater decrease in vascular sprouting compared to sorafenib. This
is contrary to what is expected as sorafenib is typified as an anti-angiogenic drug and, thus,
specifically acts on the vasculature, whereas doxorubicin is typified as a cytotoxic drug.
Furthermore, in animal models, doxorubicin is shown to have no effect on the vasculature
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of orthotopic and subcutaneous human xenografts. [142] However, sorafenib acts mainly
on the vasculature by affecting blocking VEGF and PDGF receptors, and affects
angiogenesis, the formation of new vessels from pre-existing vessels. Sorafenib is not a
vascular disrupting drug and therefore does not destroy the pre-existing vasculature.
Doxorubicin by contrast is a cytotoxic drug and would destroy the pre-existing vasculature,
as well as other cells. As to why doxorubicin seems to be effective in this in vitro model,
but seems to have no effect in the animal model, can be explained in terms of tumor drug
delivery. As mentioned previously the tumor vasculature is tortuous and as such it is
difficult to effectively deliver drugs to the tumor and for that matter the vasculature itself.
Our model does not have any barrier to prevent the doxorubicin from affecting the vascular
sprouts, and as such the effective concentration of doxorubicin is much higher. Similarly
the rat aortic ring assay does not have any such barrier either and so our model is therefore
no better or worse in that regard. A simple solution to this dissimilarity would be to add a
second layer of gel to serve as a barrier and, thus, lower the effective concentration of
doxorubicin.

4.4.3 Anastomosis
Anastomosis is the ideal condition to meet the requirement of Aim 3 as we seek to join the
potential vasculature within the spheroids with the cell coated fiber/tube carrying the drug
in question. HUVEC spheroids are incubated on Matrigel with either a cell coated fiber or
tube, and show the hallmarks of anastomosis. In Figure 4.11 and Figure 4.12, both the
spheroids and the fiber/tube are able to form vascular sprouts, though not in any specific
direction as evident by the “sun” like formation of sprouts around the spheroids.
Eventually, over the course of 7 days, vascular sprouts will continue growing until they
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meet each other as evident in Figure 4.11 C). Upon closer inspection at 20x magnification
on day 6 as shown by Figure 4.12 B), the vascular sprouts from two different sources will
interact with one another, resulting in the anastomosis of the spheroid to the cell coated
fiber/tube. However, due to either a lack of pericytes and/or flow, no lumen is witnessed
to form inside this vasculature. In the future, these properties need to be included.
A manner in which this model may differ from in vivo conditions is the origin of
the vasculature within the liver cancer. In this model, the liver cancer is modeled by the
triculture HUVEC spheroids and the origin of the vasculature within this model of the liver
cancer is HUVEC cells that originate from the cell media of the hanging drop. This
arrangement does not recapitulate the most common origin narrative of the tumor
vasculature. Briefly, tumors grow to a size such that oxygen is no longer able to diffuse
properly, resulting in hypoxia and the upregulation of pro-angiogenic factors which causes
vascular sprouting from a local blood vessel to restore oxia. Hence, the vasculature’s origin
is from outside the liver cancer and this seems to have been proven by Ghanekar et al. in
which a male human cancer xenograft is implanted into a female rat. [143] The vasculature
from the xenograft positively stains for rat CD31 and not only that, fluoresces for female
chromosomes, showing the origin of the vasculature is from the rat, or outside the cancer.
The local blood vessel in our model is the cell coated tube which should therefore provide
the vasculature for the spheroid, however, due to the limited lifespan of an in vitro model
it may not be possible for this to occur. The process of cancer vascularization takes years
in human beings and weeks in the rat. Therefore, in order to speed up the process, HUVEC
cells are included into the spheroids.
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Although, the local blood vessel narrative is the most widely held narrative
regarding vascular origins, there may be alternative narratives involving cancer stem cells
and bone marrow endothelial progenitor cells. In the cancer stem cells/tumor progenitor
cell narrative, cancer stem cells/tumor progenitor cells, stem cells present within the tumor
can differentiate into endothelial cells. [144, 145] Similarly, in the bone marrow endothelial
progenitor cells narrative, bone marrow derived endothelial progenitor cells travel through
the blood stream and can colonize in the tumor where they differentiate into the endothelial
cells. [146, 147] Based on these alternative narratives, it may be possible to justify our
model.

4.4.4 Migration
Migration is not an ideal condition to meet the requirement of Aim 3 as a vasculature is not
formed between the spheroid and fiber/tube as would be formed between the solid tumor
and the blood vessel in vivo. HUVEC spheroids are incubated on Matrigel with either a
cell coated fiber or tube, and show the hallmarks of migration. In Figure 4.13 and Figure
4.14, the spheroids and the cell coated tube do not form as many vascular sprouts as the
anastomosis condition, rather the spheroids migrate toward the cell coated fiber or tube
over the course of several days. Migration can be explained by the presence of fibroblasts
within the spheroids and endothelial cell coated on the tube. Fibroblasts migrate toward
sources of VEGF and endothelial cells provide a source of VEGF. Thus, the fibroblasts
surrounding the spheroid may cause the entirety of the spheroid to migrate toward the
endothelial cells on the cell coated tube. Similar phenomena are witnessed in transwell
membranes in which the membranes coated with VEGF and/or endothelial cells. [148]
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Altering the stiffness of the gel in which spheroids are embedded may prevent
migration. Addition of collagen gel or other ECM analogue would increase stiffness and
increase of hydrogel stiffness is known to prevent migration in other spheroid cultures.
[149] However, a difficulty in manipulating stiffness of Matrigel, is that the concentration
of protein within the Matrigel is unknown and differs amongst manufacturers and batches.

4.4.5 Fluorescent Injection
Fluoresecent FITC-dextran and doxorubicin are injected into a model containing HUVEC
triculture spheroids and RAEC cell coated tubes incubated on Matrigel for 7 days, and
serve as proxies of anti-angiogenic drugs entering into the model. The results show the
capricious nature of the model. In the FITC-dextran images in Figure 4.15 C), green
fluorescence can be seen to enter the vascular sprouts, proving the existence of a nascent
lumen. However, in the doxorubicin images in Figure 4.16 C), none of the vascular sprouts
have red fluorescence within. Similarly, in the doxorubicin images, red fluorescence can
be seen in the area encompassing the spheroid, but in FITC dextran images, green
fluorescence cannot be seen in the area encompassing the spheroid. Neither FITC dextran,
nor doxorubicin are specific dyeing agents and so there is no more reason why one should
be seen in a particular site versus the other. The images testify to the capricious nature of
the model, in that sometimes vascular sprouts will form a lumen allowing FITC-dextran
inside, while sometimes a spheroid will have vascularized allowing doxorubicin inside.
Nevertheless, that these fluorescent compounds are able to enter into the vascular sprouts
and spheroid show some success for the model in that a drug could enter through the
vascular sprouts and that a drug could enter into the spheroid, though separately. Ideally,
the fluorescent compound acting as a proxy for a drug should have entered through the
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vascular sprout and then into the spheroid. Overall, the results of this experiment, confirm
our hypothesis as the fluorescent compound, acting as the anti-cancer drug, is successfully
transported from the cell coated tube, acting as the blood vessel, into the spheroid, acting
as the spheroid.
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CHAPTER 5
CONCLUSION

The purpose of this study is to develop an in vitro model of liver cancer that recapitulates
aspects of cancer in vivo as a platform to anti-cancer drugs. To accomplish this goal, the
study is divided into three different aims.
The first aim is to develop spheroids as an anti-cancer drug platform. To this end
homospheroids containing HepG2 cells are developed using the hanging drop method.
Such a culture is able to maintain cell viability of the HepG2 cells. When homospheroids
are exposed to the anti-cancer drug doxorubicin, the culture shows a greater resistance to
the drug than a 2D monolayer, similar to resistance expected in vivo. When spheroids are
cultured with HepG2 and fibroblast cells together as heterospheroids, they show a greater
resistance to doxorubicin than homospheroids without collagen gel. When both types of
spheroids are cultured in collagen gel, they both show high viability following drug
exposure, but no significant difference. The difference between homospheroids and
heterospheroids with or without collagen gel shows that the collagen gel may mask any of
the effect of the fibroblast toward drug resistance. Similarly, cytochrome p450 activity is
preserved in collagen gel after exposure to the anti-cancer drug as compared in the non-gel
condition. A question not answered in this study is whether the collagen gel as a physical
barrier or as a substrate is responsible for drug resistance/increased viability.
The second aim of our study is developing chitosan based microfiber scaffolds as a
tissue engineered blood vessel to promote angiogenesis. The material chitosan is not
conducive to binding cells, so must be chemically modified to allow cell adhesion. To this
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end, chitosan is crosslinked with EDC/NHS to heparin and adsorbed with fibronectin. To
test this, chitosan film is first modified. To confirm heparin’s binding to chitosan, toluidine
blue staining and FTIR are used to analyze heparin crosslinked chitosan films, and shows
its presence. A cell adhesion study using phase imagery, Actin/DAPI staining, and Alamar
blue assay shows that chitosan film crosslinked with EDC/NHS to heparin and adsorbed
with fibronectin is able to promote cell adhesion and proliferation. Similar modification to
a chitosan wetspun fiber shows similar results in that cells are able to adhere to the construct
as shown by phase imagery and Actin/DAPI staining. A chitosan wetspun fiber crosslinked
with EDC/NHS to heparin and adsorbed with VEGF is immunostained with anti-Flk-1 and
shows that the fiber is able to bind VEGF. VEGF is a critical growth factor in angiogenesis,
but is expensive, and so fibronectin is used instead for the present study. For future studies,
the use of VEGF would be used to promote angiogenesis as it aids in the formation of
vascular sprouts. In order to hollow out a lumen within the construct to allow distribution
of anti-cancer drugs similar to distribution of anti-cancer drugs in vivo, a combination of
acidic and enzymatic degradation is employed. Non-cell coated and trypan blue stained
fibers are exposed to acidic and enzymatic degradation conditions as a preliminary to cell
coated fiber experiments and shows that the fiber does not degrade evenly. When cell
coated fibers are exposed to acids and enzymes, swelling/bursting occurs which breaks the
construct. Due to the inability to degrade chitosan fiber without destroying the cell
construct as a result of present circumstance, an alternative method is proposed using
chitosan electrospun mats to form tubes. Chitosan electrospun mats are manufactured by
rolling the mat around a needle followed by neutralizing, washing, drying, and removal to
form a tube. The tube is treated similarly to the fiber and shows the ability to maintain cell
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viability as shown by live and Hoechst staining. Furthermore, when embedded in Matrigel,
the tube is able to promote vascular sprouting and angiogenesis.
The third aim of our study is to construct a vascularized liver cancer model using
spheroids and cell coated tube. As such triculture spheroids and cell coated tube are
embedded on Matrigel. Triculture spheroids, combining HepG2, fibroblasts, and
endothelial cells, embedded on Matrigel result in vascular sprouts which can be used to
help form a physical connection between the spheroid and the tube. Besides this, triculture
spheroids on Matrigel can be used as an alternative to the aortic ring assay. Vascular sprouts
emanating from the triculture spheroid can be used as a measure of how anti-cancer drugs
affect angiogenesis. The anti-cancer drugs doxorubicin and sorafenib are both able to halt
vascular sprouting growth and/or reverse it, similar to the aortic ring assay.
Spheroids are either observed to anastomize, in which vascular sprouts from both the
spheroids and tube interact with one another, or migrate, in which the spheroid migrates
onto the tube. When fluorescent compounds FITC dextran and doxorubicin are injected
into the system, the fluorescent compounds are shown in some of the vascular sprouts and
within the spheroid region showing the presence of a nascent lumen.
Overall, the model shows varying degrees of success as a drug cancer model by
showing greater resistance similar to cancer in vivo. Aim 1 shows success as a model in
that spheroids with different cell types and in collagen gel are able to resist the anti-cancer
drug. Homopsheroids are able to resist drugs better than 2D cultures due to their geometry
and gel system. Both homospheroids and heterospheroids are shown to promote drug
resistance in collagen gels.
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For Aim 2, chitosan wetspun fibers require alternative methods to form a tissue
engineered blood vessel with a lumen, however, at present chitosan electrospun tubes show
success in being a platform for cells as well as containing a lumen. Chitosan film is shown
to be chemically modified with EDC/NHS to heparin and adsorbed with fibronectin and
able to adhere and proliferate cells. The chitosan wetspun fiber shows similar results. When
the fiber is degraded to form a lumen, the fiber is shown to swell and ultimately, cause
bursting of the cells coated on the construct. Unable to form a tissue engineered blood
vessel using the chitosan wetspun fiber, an alternative chitosan electospun mat tube is used
instead. Processed similarly to the chitosan wetspun fiber, electrospun tubes are able to
adhere cells and form vascular sprouts on Matrigel.
For Aim 3, spheroids and cell coated tube are combined together on Matrigel in
order to form a vascularized liver model. Triculture spheroids exhibit vascular sprouts
which after exposure to anti-cancer drugs, show retarded growth, similar to that of the
aortic ring assay. Triculture spheroids on Matrigel with cell coated tubes, show
anastomosis and migration. Anastomosis between the cells coating the tube and the
spheroid is the desired outcome in order to form a vascularized liver model as it mimics
angiogenesis in vivo in which blood vessels vascularize the tumor. Migration is an
undesired event as it does not mimic angiogenesis and better models the phenomena of
vascular co-option. Fluorescent compounds are injected into the model to illuminate the
path by which these drugs travel through the model, as well as expose any open lumens.
When fluorescent compounds FITC-dextran and doxorubicin are injected into the model,
they show the presence of nascent lumen in the vascular sprouts and presence in the
spheroid showing the possibility of lumens within the spheroid.
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For future studies, further characterization studies can be employed on the
vascularized cancer model to determine the mechanism by which combination therapy of
sorafenib and doxorubicin is able to prolong overall survival in patients. Various theories
exist as to why combination therapy works. The obvious theory is that combination therapy
simply works because of the additive effects of multiple types of anti-cancer drugs.
However, especially with anti-angiogenic drugs, the anti-angiogenic drugs may be able to
restore the vasculature in what is known as vascular normalization.[150] As previously
mentioned, blood vessels within cancer are leaky, as a result the concentration of anticancer drugs inside the cancer decreases. One of the reasons for the leaky vessels is the
overabundance of VEGF. Anti-angiogenic drugs affect VEGF and, thus, may result the
restoration/normalization of the vessels such that anti-cancer drugs more readily enter into
the tumor. To characterize this in the model, the model is exposed to sorafenib and the
vasculature that exists between the spheroids and tube is monitored following the injection
of doxorubicin. The intensity of the red fluorescence representing the doxorubicin
concentration within the vasculature is then used to determine whether the sorafenib has
caused vascular normalization.
Overall, the vascularized liver model shows limited success. The vascularized
model is able to form connections between the spheroid and the cell coated tube which
could be used for the transport of anti-angiogenic drugs such as sorafenib into the spheroid,
similar to what is expected in cancer when the drug is transported into the tumor. However,
the advent of migration in the model confounds this expectation. Of course, each spheroid
represents a single tumor and the varied fates demonstrated by each of the spheroid of
either anastomizing, migrating, or remaining still, may make the model representative of
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the fate of tumors in the entire body. Although, this would make the model biomimetic, it
would be troublesome to study the effects of the co-administration of doxorubicin and
sorafenib as the model is not consistent throughout.
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